UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, ~~2020~~2021

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number: 000-09908

TOMI ENVIRONMENTAL SOLUTIONS, INC.

(Exact name of registrant as specified in its charter)

Florida	59-1947988
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
~~incorporation or organization)~~

~~9454 Wilshire Blvd., Penthouse, Beverly Hills, CA 90212~~8430 Spires Way, Frederick, Maryland 21701
(Address of principal executive offices) (Zip Code)

(800) 525-1698
(Registrant’s telephone number, including area code)

~~Not Applicable~~
~~(Former name, former address and former fiscal year, if changed since last report)~~

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.01 per share		TOMZ		~~OTC Markets Group Inc.~~Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☐☒	Smaller reporting company ☒
	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of May 6, ~~2020,~~2021, the registrant had ~~133,517,083~~16,811,513 shares of common stock outstanding.

QUARTERLY REPORT ON FORM 10-Q FOR THE QUARTER ENDED MARCH 31, ~~2020~~2021

TABLE OF CONTENTS

		Page

~~FORWARD-LOOKING~~FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q, ~~(this “Form 10-Q”)~~or this Form 10-Q, contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, ~~(the “Securities Act”),~~or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, ~~(the “Exchange Act”),~~or the Exchange Act, and we intend that such forward looking statements be subject to the safe harbors created thereby. For this purpose, any statements contained in this Form 10-Q, except for historical information, may be deemed forward-looking statements. You can generally identify forward-looking statements as statements containing the words “will,” “would,” “believe,” “expect,” “estimate,” “anticipate,” “intend,~~” “estimate,~~” “assume,” “can,” “could,” “plan,” “predict,” “should” or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our businesses, or other characterizations of future events or circumstances are forward-looking statements.

The forward-looking statements included herein are based on current expectations of our management based on available information and involve a number of risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond our control. As such, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors, some of which are listed under the section “Risk Factors” in our most recent Annual Report on Form 10-K. Readers should carefully review these risks, as well as the additional risks described in other documents we file from time to time with the Securities and Exchange Commission. In light of the significant risks and uncertainties inherent in the forward-looking information included herein, the inclusion of such information should not be regarded as a representation by us or any other person that such results will be achieved, and readers are cautioned not to place undue reliance on such forward-looking information. Except as required by law, we undertake no obligation to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

P~~ART I: FINANCIAL INFORMATION~~

I~~tem 1. Financial Statements.~~

~~TOMI ENVIRONMENTAL SOLUTIONS, INC.~~

~~CONDENSED CONSOLIDATED BALANCE SHEET~~

ASSETS


Current Assets:

March 31, 2020
(Unaudited)

December 31,
2019

Cash and Cash Equivalents
$3,755,816
$897,223
Accounts Receivable - net
  3,146,197
  1,494,658
Inventories (Note 3)
  635,529
  2,315,214
Vendor Deposits (Note 4)
  1,266,560
  141,052
Prepaid Expenses
  170,856
  187,664
       Total Current Assets
  8,974,958
  5,035,811



Property and Equipment – net (Note 5))
  1,257,831
  1,367,864



Other Assets:


Intangible Assets – net (Note 6)
  845,663
  939,010
Operating Lease - Right of Use Asset (Note - 7)
  664,198
  674,471
Capitalized Software Development Costs - net (Note 8)
  83,803
  94,278
Other Assets
  122,957
  114,033
     Total Other Assets
  1,716,621
  1,821,792
Total Assets
$11,949,410
$8,225,467

LIABILITIES AND SHAREHOLDERS’ EQUITY

Current Liabilities:

  Accounts Payable
$832,177
$713,222
  Accrued Expenses and Other Current Liabilities (Note 13)
  655,736
  450,112
  Accrued Officers Compensation
  30,383
  -
  Accrued Interest (Note 9)
  -
  66,667
  Customer Deposits (Note 15)
  1,017,533
  -
  Current Portion of Long-Term Operating Lease
  73,851
  71,510
  Convertible Notes Payable, net of discount of $0


     at December 31, 2019 (Note 9)
  -
  5,000,000
     Total Current Liabilities
  2,609,680
  6,301,511



Long-Term Liabilities:


  Long-Term Operating Lease, Net of Current Portion (Note 7)
  1,015,465
  1,034,413
     Total Long-Term Liabilities
  1,015,465
  1,034,413
     Total Liabilities
  3,625,145
  7,335,924



Commitments and Contingencies
  -
  -



Shareholders’ Equity:


      Cumulative Convertible Series A Preferred Stock;


        par value $0.01 per share, 1,000,000 shares authorized; 510,000 shares issued
        and outstanding at March 31, 2020 and December 31, 2019
  5,100
  5,100

Cumulative Convertible Series B Preferred Stock; $1,000 stated value;



       7.5% Cumulative dividend; 4,000 shares authorized; none issued


        and outstanding at March 31, 2020 and December 31, 2019
  -
  -

Common stock; par value $0.01 per share, 250,000,000 shares authorized;



       133,517,083 and 124,700,418 shares issued and outstanding


        at March 31, 2020 and December 31, 2019, respectively.
  1,335,170
  1,247,004
     Additional Paid-In Capital
  47,863,977
  43,136,683
     Accumulated Deficit
  (40,879,982)
  (43,499,244)
     Total Shareholders’ Equity
  8,324,265
  889,543
Total Liabilities and Shareholders’ Equity
$11,949,410
$8,225,467




The accompanying notes are an integral part of the condensed consolidated financial statements.

~~TOMI ENVIRONMENTAL SOLUTIONS, INC.~~

~~CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS~~

~~(UNAUDITED)~~

For The Three Months Ended

March 31,

2020

2019

   Sales, net
$7,053,418
$1,252,658
   Cost of Sales
  2,565,410
  493,310
   Gross Profit
  4,488,008
  759,348



Operating Expenses:


   Professional Fees
  136,125
  105,481
   Depreciation and Amortization
  171,909
  176,845
   Selling Expenses
  378,645
  441,671
   Research and Development
  59,458
  92,577
   Equity Compensation Expense (Note 10)
  182,772
  80,917
   Consulting Fees
  81,545
  35,006
   General and Administrative
  818,145
  694,880
Total Operating Expenses
  1,828,599
  1,627,377
Income (loss) from Operations
  2,659,409
  (868,030)



Other Income (Expense):


   Amortization of Debt Discounts
  -
  (17,534)
   Interest Income
  542
  1,030
   Interest Expense
  (40,689)
  (50,000)
Total Other Income (Expense)
  (40,147)
  (66,504)



Income (loss) before income taxes
  2,619,261
  (934,532)
Provision for Income Taxes (Note 16)
  -
  -
Net income (loss)
$2,619,261
$(934,532)



Net income (loss) Per Common Share


    Basic
$0.02��
$(0.01)
   Diluted
$0.02
$(0.01)



Basic Weighted Average Common Shares Outstanding
  126,802,819
  124,659,307
Diluted Weighted Average Common Shares Outstanding
  144,941,677
  124,659,307

~~The accompanying notes are an integral part of the condensed consolidated financial statements.~~

~~TOMI ENVIRONMENTAL SOLUTIONS, INC.~~

~~CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS’ EQUITY~~

~~FOR THE THREE MONTHS ENDED MARCH 31, 2020~~

~~(UNAUDITED)~~

PART I: FINANCIAL INFORMATION

Item 1. Financial Statements.

TOMI ENVIRONMENTAL SOLUTIONS, INC.
CONDENSED CONSOLIDATED BALANCE SHEET


ASSETS

Current Assets:	March 31, 2021 (Unaudited)	December 31, 2020
Cash and Cash Equivalents	$3,945,658	$5,198,842
Accounts Receivable - net	3,743,430	3,716,701
Other Receivables	-	198,951
Inventories (Note 3)	4,765,455	3,781,515
Vendor Deposits (Note 4)	146,130	388,712
Prepaid Expenses	316,439	421,305
Total Current Assets	12,917,114	13,706,027

Property and Equipment – net (Note 5)	1,235,483	1,298,103

Other Assets:
Intangible Assets – net (Note 6)	720,494	722,916
Operating Lease - Right of Use Asset (Note - 7)	619,989	631,527
Capitalized Software Development Costs - net (Note 8)	41,902	52,377
Other Assets	516,230	358,935
Total Other Assets	1,898,614	1,765,755
Total Assets	$16,051,211	$16,769,885

LIABILITIES AND SHAREHOLDERS’ EQUITY

Current Liabilities:
Accounts Payable	$2,046,667	$1,501,469
Accrued Expenses and Other Current Liabilities (Note 13)	629,797	501,849
Customer Deposits	28,949	118,880
Current Portion of Long-Term Operating Lease	83,768	81,223
Total Current Liabilities	2,789,181	2,203,421

Long-Term Liabilities:
Loan Payable (Note 15)	410,700	410,700
Long-Term Operating Lease, Net of Current Portion (Note 7)	931,697	953,190
Total Long-Term Liabilities	1,342,397	1,363,890
Total Liabilities	4,131,577	3,567,311

Commitments and Contingencies	-	-

Shareholders’ Equity:
Cumulative Convertible Series A Preferred Stock;
par value $0.01 per share, 1,000,000 shares authorized; 63,750 shares issued
and outstanding at March 31, 2021 and December 31, 2020	638	638
Cumulative Convertible Series B Preferred Stock; $1,000 stated value;
7.5% Cumulative dividend; 4,000 shares authorized; none issued
and outstanding at March 31, 2021 and December 31, 2020	-	-
Common stock; par value $0.01 per share, 250,000,000 shares authorized;
16,811,513 and 16,761,513 shares issued and outstanding
at March 31, 2021 and December 31, 2020, respectively.	168,115	167,615
Additional Paid-In Capital	52,369,899	52,142,399
Accumulated Deficit	(40,619,018)	(39,108,078)
Total Shareholders’ Equity	11,919,634	13,202,574
Total Liabilities and Shareholders’ Equity	$16,051,211	$16,769,885

The accompanying notes are an integral part of the condensed consolidated financial statements.

Series A Preferred

Common Stock

Additional
Paid in

Accumulated

Total
Shareholders'

Shares

Amount

Shares

Amount

Capital

Deficit

Equity

Balance at December 31, 2019
  510,000
$5,100
  124,700,418
$1,247,004
$43,136,683
$(43,499,243)
$889,543








Equity Compensation




  209,961

  209,961
Common Stock Issued for Services Provided


  400,000
  4,000
  44,000

  48,000
Conversion of Notes Payable into Common Stock


  8,333,332
  83,333
  4,416,667

  4,500,000
Warrants exercised


  83,333
  833
  56,667

  57,500
Net Income for the three months ended March 31, 2020





  2,619,261
  2,619,261
Balance at March 31, 2020
  510,000
$5,100
  133,517,083
$1,335,170
$47,863,978
$(40,879,982)
$8,324,265

TOMI ENVIRONMENTAL SOLUTIONS, INC.
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (UNAUDITED)

	For The Three Months Ended
	March 31,
	2021	2020 (1)

Sales, net	$2,073,455	$7,053,418
Cost of Sales	838,297	2,565,410
Gross Profit	1,235,158	4,488,008

Operating Expenses:
Professional Fees	173,493	136,125
Depreciation and Amortization	83,449	171,909
Selling Expenses	474,389	378,645
Research and Development	195,620	59,458
Equity Compensation Expense (Note 10)	-	182,772
Consulting Fees	106,174	81,545
General and Administrative	1,712,366	818,145
Total Operating Expenses	2,745,491	1,828,599
Income (loss) from Operations	(1,510,333)	2,659,409

Other Income (Expense):
Interest Income	427	542
Interest Expense	(1,035)	(40,689)
Total Other Income (Expense)	(608)	(40,147)

Income (loss) before income taxes	(1,510,940)	2,619,261
Provision for Income Taxes (Note 16)	-	-
Net Income (loss)	$(1,510,940)	$2,619,261

Net income (loss) Per Common Share
Basic	$(0.09)	$0.17
Diluted	$(0.09)	$0.14

Basic Weighted Average Common Shares Outstanding	16,805,402	15,850,352
Diluted Weighted Average Common Shares Outstanding	16,805,402	18,117,710

(1) Share amounts with respect to the common stock and Convertible Series A Preferred Stock have been retroactively restated to reflect the reverse split thereof, which was effected as of the close of business on September 10, 2020. Refer to Note 10—Equity for further information.

The accompanying notes are an integral part of the condensed consolidated financial statements.

~~TOMI ENVIRONMENTAL SOLUTIONS, INC.~~

~~CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS~~

~~(UNAUDITED )~~

For the Three Months Ended
March 31,

2020

2019

Cash Flow From Operating Activities:

  Net Income (Loss)
$2,619,261
$(934,532)
  Adjustments to Reconcile Net Income (Loss) to

  .
     Net Cash Provided by (Used in) Operating Activities:


      Depreciation and Amortization
  171,909
  176,845
       Amortization of Lease Liability
  39,329
  39,644
       Amortization of Debt Discount
  -
  17,534
       Amortization of Software Costs
  10,475
  -
      Equity Compensation Expense
  182,772
  80,917
      Value of Equity Issued for Services
  48,000
  44,000
       Reserve for Bad Debt
  25,000
  (105,000)
       Inventory Reserve
  (100,000)
  -
Changes in Operating Assets and Liabilities:


      Decrease (Increase) in:


         Accounts Receivable
  (1,676,539)
  222,922
         Inventory
  1,815,942
  288,827
         Prepaid Expenses
  16,807
  6,792
         Vendor Deposits
  (1,125,508)
  (79,275)
         Other Assets
  (8,924)
  (64,914)
      Increase (Decrease) in:


         Accounts Payable
  118,955
  (475,851)
         Accrued Expenses
  232,813
  225,072
         Accrued Interest
  (66,667)
  (50,000)
         Accrued Officer Compensation
  30,383
  (40,208)
         Customer Deposits
  1,017,533
  (1,486)
          Lease Liability
  (35,865)
  -



Net Cash Provided By (Used in) Operating Activities
  3,315,678
  (648,714)



Cash Flow From Investing Activities:


   Capitalized Software Costs
  -
  (125,704)
   Purchase of Property and Equipment
  (14,585)
  (34,582)
Net Cash (Used in) Investing Activities
  (14,585)
  (160,286)




The accompanying notes are an integral part of the condensed consolidated financial statements.

TOMI ENVIRONMENTAL SOLUTIONS, INC.

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS’ EQUITY

(UNAUDITED)

For the Three Months Ended March 31, 2021

~~TOMI ENVIRONMENTAL SOLUTIONS, INC.~~

~~CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS – CONTINUED~~

~~(UNAUDITED)~~

	Series A Preferred		Common Stock
					Additional Paid	Accumulated	Total Shareholders’
	Shares	Amount	Shares	Amount	in Capital	Deficit	Equity

Balance at December 31, 2020	63,750	$638	16,761,514	$167,614	$52,142,400	$(39,108,078)	$13,202,574

Common Stock Issued for Services Provided			50,000	500	227,500		228,000
Net (Loss) for the three months ended March 31, 2021						(1,510,940)	(1,510,940)
Balance at March 31, 2021	63,750	$638	16,811,514	$168,114	$52,369,900	$(40,619,018)	$11,919,633

For the Three Months Ended March 31,

Cash Flow From Financing Activities:
2020

2019

  Proceeds from Exercise of Warrants
  57,500
  -
  Repayment of Principal Balance on Convertible Note
  (500,000)
  -
Net Cash Used in Financing Activities
  (442,500)
  -
Increase (Decrease) In Cash and Cash Equivalents
  2,858,594
  (809,000)
Cash and Cash Equivalents - Beginning
  897,223
  2,004,938
Cash and Cash Equivalents – Ending
$3,755,816
$1,195,938



Supplemental Cash Flow Information:


   Cash Paid for Interest
$107,356
$100,000
   Cash Paid for Income Taxes
$-
$800
Non-Cash Investing and Financing Activities:


  Accrued Equity Compensation
$27,189
$59,845
Conversion of Note Payable into Common Stock
$4,500,000
$-
Equipment, net Transferred to Inventory
$36,256
$-

For the Three Months Ended March 31, 2020
	Series A Preferred		Common Stock
					Additional Paid	Accumulated	Total Shareholders’
	Shares	Amount	Shares	Amount	in Capital	Deficit	Equity
Balance at December 31, 2019 (1)	63,750	$638	15,587,552	$155,876	$44,232,274	$(43,499,244)	$889,543

Equity Compensation					209,961		209,961
Common Stock Issued for Services Provided			50,000	500	47,500		48,000
Conversion of Notes Payable into Common Stock			1,041,667	10,417	4,489,584		4,500,000
Warrants and Options Exercised			10,417	104	57,396		57,500
Net Income for the three months ended March 31, 2020						2,619,261	2,619,261
Balance at March 31, 2020 (1)	63,750	$638	16,689,634	$166,897	$49,036,715	$(40,879,983)	$8,324,265

(1) Share amounts with respect to the common stock and Convertible Series A Preferred Stock have been retroactively restated to reflect the reversesplit thereof, which was effected as of the close of business on September 10, 2020. Refer to Note 10—Equity for further information.

The accompanying notes are an integral part of the condensed consolidated financial statements.

TOMI ENVIRONMENTAL SOLUTIONS, INC.
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(UNAUDITED)
	For the Three Months Ended March 31,
	2021	2020
Cash Flow From Operating Activities:
Net Income (Loss)	$(1,510,940)	$2,619,261
Adjustments to Reconcile Net Income (Loss) to
Net Cash Provided by (Used) In Operating Activities:
Depreciation and Amortization	83,449	171,909
Amortization of Right of Use Asset	39,329	39,329
Amortization of Software Costs	10,475	10,475
Equity Compensation Expense	-	182,772
Value of Equity Issued for Services	228,000	48,000
Reserve for Bad Debt	115,000	25,000
Inventory Reserve	-	(100,000)

Changes in Operating Assets and Liabilities:
Decrease (Increase) in:
Accounts Receivable	(141,729)	(1,676,539)
Inventory	(983,941)	1,815,942
Prepaid Expenses	104,866	16,807
Vendor Deposits	242,582	(1,125,508)
Other Receivables	198,951	-
Other Assets	(157,295)	(8,924)
Increase (Decrease) in:
Accounts Payable	545,198	118,955
Accrued Expenses	127,948	263,196
Accrued Interest	-	(66,667)
Customer Deposits	(89,932)	1,017,533
Lease Liability	(36,941)	(35,865)

Net Cash Provided (Used) in Operating Activities	(1,224,978)	3,315,678

Cash Flow From Investing Activities:
Purchase of Property and Equipment	(28,205)	(14,585)
Net Cash (Used) in Investing Activities	(28,205)	(14,585)

The accompanying notes are an integral part of the condensed consolidated financial statements.

TOMI ENVIRONMENTAL SOLUTIONS, INC.
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS – CONTINUED (UNAUDITED)

	For the Three Months Ended March 31,
	2021	2020
Cash Flow From Financing Activities:
Proceeds from Exercise of Warrants	-	57,500
Repayment of Principal Balance on Convertible Note	-	(500,000)
Net Cash (Used)in Financing Activities:	-	(442,500)
Increase (Decrease) In Cash and Cash Equivalents	(1,253,184)	2,858,593
Cash and Cash Equivalents - Beginning	5,198,842	897,223
Cash and Cash Equivalents – Ending	$3,945,658	$3,755,816

Supplemental Cash Flow Information:
Cash Paid For Income Taxes	$-	$-
Cash Paid For Interest	$-	$107,356
Non-Cash Investing and Financing Activities:
Accrued Equity Compensation	$-	$27,189
Conversion of Note Payable into Common Stock	$-	$4,500,000
Equipment, net Transferred to Inventory	$-	$36,256

The accompanying notes are an integral part of the condensed consolidated financial statements.

TOMI ENVIRONMENTAL SOLUTIONS, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1. DESCRIPTION OF BUSINESS

TOMI Environmental Solutions, Inc., a Florida corporation (“TOMI”, the “Company”, “we”, “our” and “us”) is a global provider of disinfection and decontamination essentials through ~~its~~our premier Binary Ionization Technology® (BIT™) platform, under which ~~it manufactures, licenses, services~~we manufacture, license, service and ~~sells its~~sell our SteraMist® brand of products, including SteraMist® BIT™, a hydrogen peroxide-based mist and fog. Our business is organized into five divisions: Healthcare, Life Sciences, TOMI Service Network, Food Safety and Commercial.

Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ is registered with the U.S. Environmental Protection Agency ~~(“EPA”)~~(EPA) and uses a low percentage hydrogen peroxide as its only active ingredient to produce a fog composed mostly of a hydroxyl radical (.OH ion), known as ionized Hydrogen Peroxide ~~(“iHP~~(iHP™”). Represented by the SteraMist® brand of products, iHP™produces a germ-killing aerosol that works like a visual non-caustic gas.

~~TOMI’s~~Our products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, bio-safety labs, pharmaceutical facilities, meat and produce processing facilities, universities and research facilities, vivarium labs, all service industries including cruise ships, office buildings, hotel and motel rooms, schools, restaurants, military barracks, police and fire departments, prisons, and athletic facilities. ~~TOMI~~Our products are also used in single-family homes and multi-unit residences. Additionally, our products have been listed on the EPA’s List N as products that help combat COVID-19 and are actively being used for this purpose.

~~TOMI’s mission is to help its customers create a healthier world through its product line in its divisions (Healthcare, Life Sciences, TOMI Service Network and Food Safety).~~

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The interim unaudited condensed consolidated financial statements included herein, presented in accordance with generally accepted accounting principles utilized in the United States of America (“GAAP”), and stated in U.S. dollars, have been prepared by ~~the Company,~~us, without an audit, pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations, although ~~the Company believes~~we believe that the disclosures are adequate to make the information presented not misleading.

These financial statements reflect all adjustments, consisting of normal recurring adjustments, which, in the opinion of management, are necessary for fair presentation of the information contained therein. These unaudited condensed consolidated financial statements should be read in conjunction with ~~the~~our audited financial statements ~~of the Company~~ for the year ended December 31, ~~2019~~2020 and notes thereto which are included in the Annual Report on Form 10-K previously filed with the SEC on March 30, ~~2020. The Company follows~~2021. We follow the same accounting policies in the preparation of interim reports. The results of operations for the interim periods covered by this Form 10-Q may not necessarily be indicative of results of operations for the full fiscal year or any other interim period.

Principles of Consolidation

The accompanying condensed consolidated financial statements include the accounts of TOMI and its ~~wholly-owned~~wholly owned subsidiary, TOMI Environmental Solutions, Inc., a Nevada corporation. All significant intercompany accounts and transactions have been eliminated in consolidation.

Reclassification of Accounts

Certain reclassifications have been made to prior-year comparative financial statements to conform to the current year presentation. These reclassifications had no effect on previously reported results of operations or financial position.

Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the accompanying condensed consolidated financial statements and the accompanying notes. Actual results could differ materially from these estimates. On an ongoing basis, we evaluate our estimates, including those related to accounts receivable, inventory, fair values of financial instruments, intangible assets, useful lives of intangible assets and property and equipment, fair values of stock-based awards, income taxes, and contingent liabilities, among others. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of our assets and liabilities.

Fair Value Measurements

The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following:

~~Level 1:~~

Level 1:	Quoted prices in active markets for identical assets or liabilities. ~~Level2:~~ Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data or substantially the full term of the assets or liabilities. ~~Level 3:~~ ~~Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities.~~
Level 2:	Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3:	Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities.

Our financial instruments include cash and cash equivalents, accounts receivable, accounts payable and accrued expenses. All these items were determined to be Level 1 fair value measurements.

The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximated fair value because of the short maturity of these instruments.

Cash and Cash Equivalents

For purposes of the statement of cash flows, cash and cash equivalents includes cash on hand, held at financial institutions and other liquid investments with original maturities of three months or less. At times, these deposits may be in excess of insured limits.

Accounts Receivable

Our accounts receivable are typically from credit worthy customers or, for certain international customers, are supported by pre-payments. For those customers to whom we extend credit, we perform periodic evaluations of ~~them~~their status and maintain allowances for potential credit losses as deemed necessary. We have a policy of reserving for doubtful accounts based on our best estimate of the amount of potential credit losses in existing accounts receivable. We periodically review our accounts receivable to determine whether an allowance is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt. Account balances deemed to be uncollectible are charged to the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. Bad debt expense for the three months ended March 31, 2021 and 2020 was $115,000 and ~~2019 was~~ $25,000, ~~and $58,490,~~ respectively.

At March 31, ~~2020~~2021 and December 31, ~~2019,~~2020, the allowance for doubtful accounts was ~~$135,000~~$505,000 and ~~$110,000,~~$390,000, respectively.

~~As of March 31, 2020, one customer accounted for 12% of accounts receivable. As of December 31, 2019, three customers accounted for 37% of accounts receivable.~~

~~One customer/distributor accounted for 31% of net revenue for the three months ended March 31, 2020 and two customers accounted for 45% of net revenue for the three months ended March 31, 2019.~~

Inventories

Inventories are valued at the lower of cost or market using the first-in, first-out (FIFO) method. Inventories consist primarily of finished ~~goods~~.goods.

We expense costs to maintain certification to cost of goods sold as incurred.

We review inventory on an ongoing basis, considering factors such as deterioration and obsolescence. We record an allowance for estimated losses when the facts and circumstances indicate that particular inventories may not be usable. Our reserve for obsolete inventory was $0 ~~and $100,000~~ as of March 31, ~~2020~~2021 and December 31, ~~2019,~~2020, respectively.

Property and Equipment

We account for property and equipment at cost less accumulated depreciation. We compute depreciation using the straight-line method over the estimated useful lives of the assets, generally three to five years. Depreciation for equipment, furniture and fixtures and vehicles commences once placed in service for its intended use. Leasehold improvements are amortized using the straight-line method over the lives of the respective leases or service lives of the improvements, whichever is shorter.

Leases

In February 2016, the FASB issued ASU No. 2016-02 ~~(“ASC 842”)~~(ASC 842), Leases, to require lessees to recognize all leases, with certain exceptions, on the balance sheet, while recognition on the statement of operations will remain similar to current lease accounting. Subsequently, the FASB issued ASU No. 2018-10, Codification Improvements to Topic 842, Leases, ASU No. 2018-11, Targeted Improvements, ASU No. 2018-20, Narrow-Scope Improvements for Lessors, and ASU 2019-01, Codification Improvements, to clarify and amend the guidance in ASU No. 2016-02. ASC 842 eliminates real estate-specific provisions and modifies certain aspects of lessor accounting. This standard is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted. We adopted ASC 842 as of January 1, 2019 using the modified retrospective basis with a cumulative effect adjustment as of that date. In addition, we elected the package of practical expedients permitted under the transition guidance within the ~~new~~ standard, which allowed us to carry forward the historical determination of contracts as leases, lease classification and not reassess initial direct costs for historical lease arrangements. Accordingly, previously reported financial statements, including footnote disclosures, have not been recast to reflect the application of the ~~new~~ standard to all comparative periods presented.

Operating lease assets are included within operating lease right-of-use assets, and the corresponding operating lease liabilities are recorded as current portion of long-term operating lease, and within long-term liabilities as long-term operating lease, net of current portion on our condensed consolidated balance sheet as of March 31, ~~2020~~2021 and December 31, ~~2019.~~2020.

We have elected not to present short-term leases on the condensed consolidated balance sheet as these leases have a lease term of 12 months or less at lease inception and do not contain purchase options or renewal terms that we are reasonably certain to exercise. All other lease assets and lease liabilities are recognized based on the present value of lease payments over the lease term at commencement date. Because most of our leases do not provide an implicit rate of return, we used our incremental borrowing rate based on the information available at adoption date in determining the present value of lease payments.

Capitalized Software Development Costs

In accordance with ASC 985-20 regarding the development of software to be sold, leased, or marketed, ~~the Company expenses~~we expense such costs as they are incurred until technological feasibility has been established, at and after which time those costs are capitalized until the product is available for general release to customers. The periodic expense for the amortization of capitalized software development costs will be included in cost of sales. Amortization expense for the three months ended March 31, 2021 and 2020, was ~~$10,475.~~$10,475, respectively.

Accounts Payable

As of March 31, ~~2020, and December 31, 2019,~~2021, one vendor accounted for approximately ~~33% and 40%~~60% of accounts ~~payable, respectively.~~payable. As of December 31, 2020, two vendors accounted for approximately 32% of accounts payable.

For the three months ended March 31, 2021, two vendors accounted for 64% of cost of sales. For the three months ended March 31, 2020, ~~and 2019,~~ one vendor accounted for 89% ~~and 67%~~ of cost of ~~sales, respectively.~~sales.

Accrued Warranties

Accrued warranties represent the estimated costs, if any, that will be incurred during the warranty period of our products. We estimate the expected costs to be incurred during the warranty period and record the expense to the condensed consolidated statement of operations at the date of sale. Our ~~manufacturer assumes~~manufacturers assume the warranty against product defects ~~for one year~~ from date of sale, which we extend to our customers upon sale of the product. We assume responsibility for product reliability and results. As of March 31, ~~2020,~~2021, and December 31, ~~2019,~~2020, our warranty reserve was ~~$60,000 and $30,000, respectively~~$68,000. (See Note 14).

Income Taxes

Deferred income tax assets and liabilities are determined based on differences between the financial statement reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws in effect when the differences are expected to reverse. The measurement of deferred income tax assets is reduced, if necessary, by a valuation allowance for any tax benefits that are, on a more likely than not basis, not expected to be realized in accordance with Accounting Standards Codification ~~(“ASC”)~~(ASC) guidance for income taxes. Net deferred tax benefits have been fully reserved at March 31, ~~2020~~2021 and December 31, ~~2019.~~2020. The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted.

Net Income (Loss) Per Share

Basic net income or (loss) per share is computed by dividing ~~the Company’s~~our net income or (loss) by the weighted average number of shares of common stock outstanding during the period presented. Diluted income or (loss) per share is based on the treasury stock method and includes the effect from potential issuance of shares of common stock, such as shares issuable pursuant to the exercise of options and warrants and conversions of preferred stock or debentures.

Potentially dilutive securities as of March 31, ~~2020~~2021 consisted of ~~16,798,858~~1,880,383 shares of common stock issuable upon exercise of outstanding warrants, ~~830,000~~132,500 shares of common stock issuable upon outstanding options and ~~510,000~~63,750 shares of common stock issuable upon conversion of outstanding shares of Preferred A stock (“Convertible Series A Preferred Stock”).

Potentially dilutive securities as of March 31, ~~2019~~2020 consisted of ~~9,259,250 shares of common stock from convertible debentures, 26,800,611~~2,099,857 shares of common stock issuable upon exercise of outstanding warrants, ~~620,000~~103,750 shares of common stock issuable upon outstanding options and ~~510,000~~63,750 shares of common stock issuable upon conversion of outstanding shares of Preferred A stock (“Convertible Series A Preferred Stock”)~~. Diluted and basic weighted average shares are the same, as potentially dilutive shares are anti-dilutive.~~

Diluted net income or (loss) per share is computed similarly to basic net income or (loss) per share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if the potential shares of common stock had been issued and if such additional shares were dilutive. Options, warrants, and preferred stock ~~and shares associated with the conversion~~ of ~~debt to purchase~~ approximately ~~16.7~~2.1 million and ~~27.6~~2.2 million shares of common stock were outstanding at March 31, ~~2020~~2021 and December 31, ~~2019,~~2020, respectively, but were excluded from the computation of diluted net loss per share at ~~December~~March 31, ~~2019~~2021 due to the anti-dilutive effect on net loss per share.

For the Three Months Ended March 31,
(Unaudited)

2020

2019

Net Income (Loss)
$2,619,261
$(934,532)
Adjustments for convertible debt - as converted


Interest on convertible debt
  40,689
  50,000
Amortization of debt discount on convertible debt
  -
  17,534
Net income (loss) attributable to common shareholders
$2,659,950
$(866,998)
Weighted average number of shares of common stock outstanding:


Basic
  126,802,819
  124,659,307
Diluted
  144,941,677
  124,659,307
Net income (loss) attributable to common shareholders per share:


Basic
$0.02
$(0.01)
Diluted
$0.02
$(0.01)

	For the Three Months Ended March 31, (Unaudited)
	2021	2020
Net Income (Loss)	$(1,510,940)	$2,619,261
Adjustments for convertible debt - as converted
Interest on convertible debt	-	40,689
Net income (loss) attributable to common shareholders	$(1,510,940)	$2,659,950
Weighted average number of shares of common stock outstanding:
Basic	16,805,402	15,850,352
Diluted	16,805,402	18,117,709
Net income (loss) attributable to common shareholders per share:
Basic	$(0.09)	$0.17
Diluted	$(0.09)	$0.15

The following provides a reconciliation of the shares used in calculating the per share amounts for the periods presented:

For the Three Months

Ended March 31

(Unaudited)

2020

2019

Numerator:

Net Income (Loss)
$2,619,261
$(934,532)

	For the Three Months Ended March 31, (Unaudited)
	2021	2020
Numerator:
Net Income (Loss)	$(1,510,940)	$2,619,261
Denominator:
Basic weighted-average shares	126,802,819	124,659,307	16,805,402	15,850,352
Effect of dilutive securities
Warrants	16,798,858	-	-	2,099,857
Convertible Debt	-		-
Options	830,000	-	-	103,750
Preferred Stock	510,000	-	-	63,750
Diluted Weighted Average Shares	144,941,677	124,659,307	16,805,402	18,117,709

Net Income (Loss) Per Common Share:
Basic	$0.02	$(0.01)	$(0.09)	$0.17
Diluted	$0.02	$(0.01)	$(0.09)	$0.14

Note: Warrants, options and preferred stock for the three months ended March 31, ~~2019~~2021 are not included in the computation of diluted weighted average shares as such inclusion would be anti-dilutive.

Income (loss) from Operations Data:

Income (Loss) from Operations	$(1,510,333)	$2,659,409

Basic and Diluted Weighted Average Shares
Basic	16,805,402	15,850,352
Diluted	16,805,402	18,117,709
Basic and Diluted Income (loss) Per Common Share
Basic	$(0.09)	$0.17
Diluted	$(0.09)	$0.15

Income (loss) from Operations Data:

Income (Loss) from Operations
$2,659,409
$(868,030)
Basic and Diluted Weighted


  Average Shares


Basic
  126,802,819
  124,659,307
Diluted
  144,941,677
  124,659,307
Basic and Diluted Income (loss) Per Common Share


Basic
$0.02
$(0.01)
Diluted
$0.02
$(0.01)

Revenue Recognition

We recognize revenue in accordance with Financial Accounting Standards Board ~~(“FASB”)~~(FASB) Accounting Standards Update ~~(“ASU”)~~(ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606). ~~The Company recognizes~~We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligation(s). At contract inception, we assess the goods or services promised within each contract, assess whether each promised good or service is distinct and identify those that are performance obligations.

~~The Company~~We must use judgment to determine: a) the number of performance obligations based on the determination under step (ii) above and whether those performance obligations are distinct from other performance obligations in the contract; b) the transaction price under step (iii) above; and c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above.

Title and risk of loss generally pass to our customers upon shipment. Our Customers include end users as well as dealers and distributors who market and sell our products. Our revenue is not contingent upon resale by the dealer or distributor, and we have no further obligations related to bringing about resale. Shipping and handling costs charged to customers are included in Product Revenues. The associated expenses are treated as fulfillment costs and are included in Cost of Revenues. Revenues are reported net of sales taxes collected from Customers.

Disaggregation of Revenue

The following table presents our revenues disaggregated by revenue source.

Product and Service Revenue

	For the three months ended March 31, (Unaudited)
	2021	2020
SteraMist Product	$1,661,000	$6,638,000
Service and Training	412,000	415,000
Total	$2,073,000	$7,053,000

For the three months ended March 31,
(Unaudited)

2020

2019

SteraMist Product
$6,638,000
$1,029,000
Service and Training
415,000
224,000
Total
$7,053,000
$1,253,000

Revenue by Geographic Region

	For the three months ended March 31, (Unaudited)
	2021	2020
United States	$1,804,000	$3,569,000
International	269,000	3,484,000
Total	$2,073,000	$7,053,000

For the three months ended March 31,
(Unaudited)

2020

2019

United States
$3,569,000
$1,136,000
International
3,484,000
117,000
Total
$7,053,000
$1,253,000

Product revenue includes sales from our standard and customized equipment, solution and accessories sold with our equipment. Revenue is recognized upon transfer of control of promised products to customers in an amount that reflects the consideration we expect to receive in exchange for those products.

Service and training revenue include sales from our high-level decontamination and service engagements, validation of our equipment and technology and customer training. Service revenue is recognized as the agreed upon services are rendered to our customers in an amount that reflects the consideration we expect to receive in exchange for those services.

Costs to Obtain a Contract with a Customer

We apply a practical expedient to expense costs as incurred for costs to obtain a contract with a customer when the amortization period would have been one year or less. We generally expense sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within selling expenses.

Contract Balances

As of March 31, ~~2020~~2021, and December 31, ~~2019~~2020 we did not have any unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.

Arrangements with Multiple Performance Obligations

Our contracts with customers may include multiple performance obligations. We enter into contracts that can include various combinations of products and services, which are primarily distinct and accounted for as separate performance obligations.

Significant Judgments

Our contracts with customers for products and services often dictate the terms and conditions of when the control of the promised products or services is transferred to the customer and the amount of consideration to be received in exchange for the products and services.

Equity Compensation Expense

We account for equity compensation expense in accordance with FASB ASC 718, “Compensation—Stock Compensation.” Under the provisions of FASB ASC 718, equity compensation expense is estimated at the grant date based on the award’s fair value.

On July 7, 2017, our shareholders approved the 2016 Equity Incentive Plan, ~~(the “2016 Plan”).~~or the 2016 Plan. The 2016 Plan authorizes the grant of stock options, stock appreciation rights, restricted stock, restricted stock units and performance units/shares. Up to ~~5,000,000~~2,000,000 shares of common stock are authorized for issuance under the 2016 Plan. Shares issued under the 2016 Plan may be either authorized but unissued shares, treasury shares, or any combination thereof. Provisions in the 2016 Plan permit the reuse or reissuance by the 2016 Plan of shares of common stock for numerous reasons, including, but not limited to, shares of common stock underlying canceled, expired, or forfeited awards of stock-based compensation and stock appreciation rights paid out in the form of cash. Equity compensation expense will typically be awarded in consideration for the future performance of services to us. All recipients of awards under the 2016 Plan are required to enter into award agreements with ~~the Company~~us at the time of the ~~award;~~award, and awards under the 2016 Plan are expressly conditioned upon such agreements. For the three months ended March 31, ~~2020~~2021 and ~~2019,~~2020, we issued ~~400,000 and 400,000~~50,000 shares of fully vested common stock, respectively, out of the 2016 ~~Plan.~~Plan to our directors.

Concentrations of Credit Risk

Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash and cash equivalents. We maintain cash balances at financial institutions which exceed the current Federal Deposit Insurance Corporation limit of $250,000 at times during the year.

Long-Lived Assets Including Acquired Intangible Assets

We assess long-lived assets for potential impairments at the end of each year, or during the year if an event or other circumstance indicates that we may not be able to recover the carrying amount of the asset. In evaluating long-lived assets for impairment, we measure recoverability of these assets by comparing the carrying amounts to the future undiscounted cash flows the assets are expected to generate. If our long-lived assets are considered to be impaired, the impairment to be recognized equals the amount by which the carrying value of the asset exceeds its fair market value. We base the calculations of the estimated fair value of our long-lived assets on the income approach. For the income approach, we use an internally developed discounted cash flow model that includes, among others, the following assumptions: projections of revenues and expenses and related cash flows based on assumed long-term growth rates and demand trends; expected future investments to grow new units; and estimated discount rates. We base these assumptions on our historical data and experience, industry projections, micro and macro general economic condition projections, and our expectations. We had no long-lived asset impairment charges for the three months ended March 31, ~~2020~~2021 and ~~2019.~~2020.

Advertising and Promotional Expenses

We expense advertising costs in the period in which they are incurred. Advertising and promotional expenses for the three months ended March 31, ~~2020~~2021 and ~~2019~~2020 were approximately $266,000 and $46,000, ~~and $40,000,~~ respectively.

Research and Development Expenses

We expense research and development expenses in the period in which they are incurred. For the three months ended March 31, ~~2020~~2021 and ~~2019,~~2020, research and development expenses were approximately ~~$59,000~~$196,000 and ~~$93,000,~~$59,000, respectively.

Business Segments

We currently have one reportable business segment due to the fact that we derive our revenue primarily from one product. A breakdown of revenue is presented in “Revenue Recognition” in Note 2 above.

Recent Accounting Pronouncements

~~None applicable.~~In August 2018, the FASB issued ASU No. 2018-15, “Intangibles-Goodwill and Other-Internal-Use Software (Topic 350): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract.” This guidance aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. This guidance is effective on a prospective or retrospective basis beginning on January 1, 2020, with early adoption permitted. We elected to adopt this guidance early, in 2020 on a prospective basis. The guidance did not have a material impact on our condensed Consolidated Financial Statements.

NOTE 3. INVENTORIES

Inventories consist of the following at:

	March 31, 2020 (Unaudited)	December 31, 2019	March 31, 2021 (Unaudited)	December 31, 2020
Finished goods	$613,060	$2,364,786	$4,396,528	$3,404,025
Raw Materials	22,469	50,428	368,927	377,490
Inventory Reserve	-	(100,000)
	$635,529	$2,315,214	$4,765,455	$3,781,515

NOTE 4. VENDOR DEPOSITS

At March 31, ~~2020~~2021 and December 31, ~~2019,~~2020, we maintained vendor deposits of ~~$1,266,560~~$146,130 and ~~$141,052,~~$388,712, respectively, for open purchase orders for inventory.

NOTE 5. PROPERTY AND EQUIPMENT

Property and equipment consist of the following at:

	March 31, 2020 (Unaudited)	December 31, 2019	March 31, 2021 (Unaudited)	December 31, 2020
Furniture and fixtures	$357,236		$357,236
Equipment	1,292,860	1,355,014	1,597,793	1,580,743
Vehicles	60,703		60,703
Computer and software	181,182	166,598	214,860	203,704
Leasehold improvements	362,898		386,120
Tenant Improvement Allowance	405,000		405,000
	2,659,880	2,707,449	3,021,712	2,993,507
Less: Accumulated depreciation	1,402,049	1,339,585	1,786,228	1,695,404
	$1,257,831	$1,367,864	$1,235,483	$1,298,103

For the three months ended March 31, ~~2020~~2021 and ~~2019,~~2020, depreciation was ~~$78,563~~$81,026 and ~~$84,468,~~$78,563, respectively. For the three months ended March 31, ~~2020~~2021 and ~~2019,~~2020, amortization of tenant improvement allowance was $9,798 and was recorded as lease expense and included within general and administrative expense on the consolidated statement of operations.

NOTE 6. INTANGIBLE ASSETS

Intangible assets consist of patents and trademarks related to our Binary Ionization Technology. We amortize the patents over the estimated remaining lives of the related patents. The trademarks have an indefinite life. Amortization expense was ~~$93,347~~$2,422 and ~~$92,377~~$93,347 for the three months ended March 31, 2021 and 2020, ~~and 2019,~~ respectively.

Definite life intangible assets consist of the following:

	March 31, 2020 (Unaudited)	December 31, 2019	March 31, 2021 (Unaudited)	December 31, 2020
Intellectual Property and Patents	$2,906,507		$3,000,012
Less: Accumulated Amortization	2,573,101	2,479,754	2,859,413	2,856,991
Intangible Assets, net	$333,406	$426,753	$140,599	$143,021

Indefinite life intangible assets consist of the following:

Trademarks
$512,257
$512,257

Total Intangible Assets, net
$845,663
$939,010

Trademarks	579,895	579,895
Total Intangible Assets, net	$720,494	$722,916

Approximate future amortization is as ~~follows~~:follows:

Year ~~Ended:~~Ended	Amount
April 1 – December 31, ~~2020~~2021	$~~279,000~~
~~December 31, 2021~~	~~3,000~~7,000
December 31, 2022	~~3,000~~10,000
December 31, 2023	~~3,000~~10,000
December 31, 2024	~~3,000~~10,000
December 31, 2025	10,000
Thereafter	~~42,000~~94,000
	$~~333,000~~141,000

NOTE 7. LEASES

In April 2018, we entered into a 10-year lease agreement for a new 9,000-square-foot facility that contains office, warehouse, lab and research and development space in Frederick, Maryland. The lease agreement was scheduled to commence on December 1, 2018 or when the property was ready for occupancy. The agreement provided for annual rent of $143,460, an escalation clause that increases the rent 3% year over year, a landlord tenant improvement allowance of $405,000 and additional landlord work as discussed in the lease agreement. We took occupancy of the property on December 17, 2018 and the lease was amended in March 2019 to provide for a 4-month rent holiday and a commencement date of April 1, 2019. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term.

The balances for our operating lease where we are the lessee are presented as follows within our condensed consolidated balance sheet:

Operating leases:	March 31, 2020 (Unaudited)	December 31, 2019	March 31, 2021 (Unaudited)	December 31, 2020
Assets:
Operating lease right-of-use asset	$664,198	$674,471	$619,989	$631,527
Liabilities:
Current Portion of Long-Term Operating Lease	$73,851	$71,510	$83,768	$81,223
Long-Term Operating Lease, Net of Current Portion	1,015,465	1,034,413	931,697	953,190
	$1,089,316	$1,105,923	$1,015,465	$1,034,413

The components of lease expense are as follows and are included within general and administrative expense on our condensed consolidated statement of operations:

Three Months Ended March 31, 2020
(Unaudited)

Three Months Ended March 31, 2019
(Unaudited)

  Operating lease expense
$39,329
$39,644

	For the Three Months Ended March 31, 2021 (Unaudited)	For the Three Months Ended March 31, 2020 (Unaudited)

Operating lease expense	$39,329	$39,329

Other information related to leases where we are the lessee is as follows:

	March 31, 2020 (Unaudited)	December 31, 2019	March 31, 2021 (Unaudited)	December 31, 2020
Weighted-average remaining lease term:
Operating leases	9.00 years	9.25 years	8.00 years	8.25 years

Discount rate:
Operating leases	7.00%		7.00%	7.00%

Supplemental cash flow information related to leases where we are the lessee is as follows:

	~~Three Months Ended March 31, 2020~~ ~~(Unaudited)~~	~~Three Months Ended March 31, 2019~~ ~~(Unaudited)~~
~~Cash paid for amounts included in the measurement of lease liabilities:~~	$~~35,865~~	$-

	For the Three Months Ended March 31, 2021 (Unaudited)	For the Three Months Ended March 31, 2020 (Unaudited)
Cash paid for amounts included in the measurement of lease liabilities:	$36,941	$35,865

As of March 31, ~~2020,~~2021, the maturities of our operating lease liability are as follows:

Year Ended:	Operating Lease
April 1 – December 31, ~~2020~~2021	$~~110,823~~
~~December 31, 2021~~	~~151,088~~114,148
December 31, 2022	155,621
December 31, 2023	160,290
December 31, 2024	165,098
December 31, 2025	170,051
Thereafter	~~745,183~~575,131
Total minimum lease payments	~~1,488,103~~1,340,340
Less: Interest	~~398,787~~324,875
Present value of lease obligations	~~1,089,316~~1,015,465
Less: Current portion	~~73,851~~83,768
Long-term portion of lease obligations	$~~1,015,465~~931,697

NOTE 8. CAPITALIZED SOFTWARE DEVELOPMENT COSTS

In accordance with ASC 985-20 we capitalized certain software development costs associated with updating our continuing line of product offerings. Capitalized software development costs consist of the following at:

	March 31, 2020		March 31, 2021	December 31,
	(Unaudited)	December 31, 2019	(Unaudited)	2020
Capitalized Software Development Costs	$125,704		$125,704
Less: Accumulated Amortization	(41,901)	(31,426)	(83,802)	(73,327)
	$83,803	$94,278	$41,902	$52,377

Amortization expense for the three months ended March 31, ~~2020~~2021 and ~~2019~~2020 was $10,475, ~~and $0,~~ respectively.

~~NOTE 9. CONVERTIBLE DEBT~~

In March and May 2017, we closed a private placement transaction in which we issued to certain accredited investors unregistered senior callable convertible promissory notes (the “Notes”) and three-year warrants to purchase an aggregate of 999,998 shares of common stock at an exercise price of $0.69 per share in exchange for aggregate gross proceeds of $6,000,000. The Notes bear interest at a rate of 4% per annum. $5,300,000 in principal was originally scheduled to mature on August 31, 2018 and $700,000 in principal was originally scheduled to mature on November 8, 2018, unless earlier redeemed, repurchased or converted. The Notes are convertible at the option of the holder into common stock at a conversion price of $0.54 per share. Subsequent to September 1, 2017, we may redeem the Notes that are scheduled to mature on August 31, 2018 at any time prior to maturity at a price equal to 100% of the outstanding principal amount of the Notes to be redeemed, plus accrued and unpaid interest as of the redemption date. Prior to November 8, 2018, we may redeem the Notes that are scheduled to mature on such date at any time prior to maturity at a price equal to 100% of the outstanding principal amount of the Notes to be redeemed, plus accrued and unpaid interest as of the redemption date. Interest on the Notes is payable semi-annually in cash on February 28 and August 31 of each year, beginning on August 31, 2017.NOTE 9. ~~Interest expense related to the Notes for the three months ended March 31, 2020 and 2019 was $40,689 and $50,000, respectively.~~CLOUD COMPUTING SERVICE CONTRACT

In May 2020 we entered into a cloud computing service contract. The ~~warrants were valued at $62,559 using~~contract provides for annual payments in the ~~Black-Scholes pricing model with the following assumptions: expected volatility: 104.06% –111.54%; expected dividend: $0; expected term: 3 years;~~amount of $30,409 and ~~risk-free rate: 1.49%–1.59%. We recorded the warrants’ relative fair value~~has a term of ~~$61,904~~5 years. The annual contract payments are capitalized as ~~an increase to additional paid-in capital~~a prepaid expense and amortized over a ~~discount against the related Notes.~~twelve-month period.

~~The debt discount was~~We have incurred implementation costs of $62,677 in connection with the cloud computing service contract which have been capitalized in prepaid expenses and other assets as of March 31, 2021. In accordance with ASU No. 2018-15, such implementation costs are being amortized over the ~~life of~~remaining contract terms beginning January 1, 2021, which was when the ~~Notes using the effective interest method.~~ cloud-based service contract was placed in service. Amortization expense for the three months ended March 31, ~~2020 and 2019,~~2021 was ~~$0 and $17,534, respectively.~~$3,482.

~~In February and March 2018, we extended the maturity date of the Notes—~~we extended the maturity date to April 1, 2019 for $5,300,000 of principal on the Notes and to June 8, 2019 for the remaining $700,000 Note. No additional consideration was paid or accrued by us. The stated rate of the Notes was unchanged, and the estimated fair value of the new debt approximates its carrying amount (principal plus accrued interest at the date of the modification). We determined that the modification of these Notes is not a substantial modification in accordance with ASC 470-50, “Modifications and Extinguishments”.

~~In May 2018, we offered a noteholder the option to convert its Note at a reduced conversion price of $0.46.The noteholder accepted and converted at such price.~~Pursuant to the terms of the conversion offer, an aggregate of $700,000 of principal and $5,212 of accrued interest outstanding under the Note were converted into 1,877,960 shares of common stock. We recognized an induced conversion cost of $57,201 related to the conversion.

~~In December 2018, a noteholder redeemed a note with a principal balance of $300,000 in exchange for $150,000 in cash.We recognized a gain on redemption of convertible note income in the amount of $150,000 as a result of the transaction.~~

On March 30, 2019, the two remaining noteholders agreed to extend the maturity dates of their notes totaling $5,000,000 to April 3, 2020. As part of the extensions, we agreed that if we do not make payment on or before the new maturity dates, after five (5) days written notice, the holders will have the right, but not the obligation, to convert the notes into our common shares at a conversion price of $0.11 per share or a total of 45,454,545 shares. All other provisions of the notes remain unchanged. We determined that the modification of these Notes is not a substantial modification in accordance with ASC 470-50, “Modifications and Extinguishments”.

~~In March 2020, convertible notes with a principal balance of $4,500,000 were converted~~ ~~into 8,333,332 shares of our common stock~~ at a conversion price of $0.54 per share and the remaining outstanding balance of $500,000 was repaid in the form of cash. With respect to the 999,998 warrants issued as part of the convertible note transaction, 799,999 warrants expired in March 2020. In March 2020, 83,333, warrants were exercised, and 116,666 warrants expired in May 2020.

~~Convertible notes consist of the following at:~~

	~~March 31, 2020 (Unaudited)~~	~~December 31,~~
~~Convertible notes~~	$-	$~~5,000,000~~
~~Initial discount~~	-	~~(53,873~~)
~~Accumulated amortization~~	-	~~53,873~~
~~Convertible notes, net~~	$-	$~~5,000,000~~

NOTE 10. SHAREHOLDERS’ EQUITY

Our Board of Directors (the “Board”) may, without further action by our shareholders, from time to time, direct the issuance of any authorized but unissued or unreserved shares of preferred stock in series and at the time of issuance, determine the rights, preferences and limitations of each series. The holders of such preferred stock may be entitled to receive a preference payment in the event of any liquidation, dissolution or winding-up ~~of the Company~~by us before any payment is made to the holders of our common stock. Furthermore, the Board could issue preferred stock with voting and other rights that could adversely affect the voting power of the holders of our common stock.

Reverse Stock Split

On September 9, 2020, the Board approved a reverse stock split of our common stock and our Convertible Series A Preferred Stock, in each case, at a ratio of 1-for-8 and without any change to the respective par value thereof (the “Reverse Stock Split”), and, on September 10, 2020, we filed an Articles of Amendment to our Articles of Incorporation with the Department of State of the State of Florida to effect the Reverse Stock Split. The Reverse Stock Split became effective as of September 10, 2020 (the “Effective Time”). All per-share and share amounts have been retroactively restated in this Quarterly Report on Form 10-Q for all periods presented to reflect the reverse stock split.

Convertible Series A Preferred Stock

Our authorized Convertible Series A Preferred Stock, $0.01 par value, consists of 1,000,000 shares. At March 31, ~~2020~~2021 and December 31, ~~2019,~~2020, there were ~~510,000~~63,750 shares issued and outstanding. The Convertible Series A Preferred Stock is convertible at the rate of one share of common stock for one share of Convertible Series A Preferred Stock.

Convertible Series B Preferred Stock

Our authorized Convertible Series B Preferred Stock, $1,000 stated value, 7.5% cumulative dividend, consists of 4,000 shares. At March 31, ~~2020~~2021 and December 31, ~~2019,~~2020, there were no shares issued and outstanding, respectively. Each share of Convertible Series B Preferred Stock may be converted (at the holder’s election) into two hundred shares of our common stock.

Common Stock

During the three months ended March 31, ~~2019, we issued 400,000 shares of common stock valued at $44,000 to members of our board of directors (see Note 12).~~

~~During the three months ended March 31,~~ 2020, we issued ~~400,000~~50,000 shares of fully vested common stock valued at $48,000 to members of our ~~board of directors~~Board (see Note 12).

In March 2020, ~~8,333,332~~1,041,667 shares of common stock were issued in connection with the conversion of convertible notes payable aggregating ~~$4,500,000 (see Note 9).~~$4,500,000.

In March 2020, ~~83,333~~10,417 shares of common stock were issued in connection with the exercise of warrants for which we received proceeds of $57,500.

~~Stock Options~~

~~In January 2019, pursuant to an employment agreement,~~During the three months ended March 31, 2021, we issued options to purchase an aggregate of 250,000 shares of common stock to our Chief Operating Officer, valued at $24,694. The options have an exercise price of $0.11 per share and expire in January 2024. The options were valued using the Black-Scholes model using the following assumptions: volatility: 144%; dividend yield: 0%; zero coupon rate: 2.47%; and a life of 5 years. The value of the options was expensed in the fourth quarter of 2018 and included in accrued expenses at December 31, 2018.

~~In January 2019, we issued options to purchase an aggregate of~~ 50,000 shares of common stock ~~to our Chief Financial Officer,~~ valued at ~~$4,483. The options have an exercise price~~$228,000 to members of $0.10 per share and expire in January 2024. The options were valued using the Black-Scholes model using the following assumptions: volatility: 143%; dividend yield: 0%; zero coupon rate: 2.58%; and a life of 5 years.our Board (see Note 12).

Stock Options

There were no options granted during the first quarter of 2021.

In January 2020 we issued two options to purchase an aggregate of ~~250,000~~31,250 shares of common stock to ~~the COO~~our Chief Operating Officer at an exercise price of ~~$0.10~~$0.80 and ~~$0.12~~$0.96 per share pursuant to her employment agreement with ~~the Company.~~us. The options were valued at a total of $23,595 and have a term of 5 years. We utilized the ~~Black-Scholes method~~Black-Scholesmethod to fair value the options received by the COO with the following assumptions: volatility, 135%; expected dividend yield, 0%; risk free interest rate, 1.64%; and a life of 5 years. The grant date fair value of each share of common stock underlying the options was ~~$0.09~~$0.72 and ~~$0.10.~~$0.80. The value of the stock option was included in accrued expenses at December 31, ~~2019.~~

2019

The following table summarizes stock options outstanding as of March 31, ~~2020~~2021 and December 31, ~~2019:~~2020:

					March 31, 2021
	March 31, 2020 (Unaudited)		December 31, 2019		(Unaudited)		December 31, 2020
	Number of Options	Weighted Average Exercise Price	Number of Options	Weighted Average Exercise Price	Number of Options	Weighted Average Exercise Price	Number of Options	Weighted Average Exercise Price
Outstanding, beginning of period	620,000	$0.32	320,000	$0.52	132,500	$2.72	77,500	$2.56
Granted	250,000	0.11	300,000	0.11	-		62,500	3.96
Exercised	-				-		(2,500)	0.40
Expired	(40,000)	2.10	—		-		(5,000)	16.80
Outstanding, end of period	830,000	$0.17	620,000	$0.32	132,500	$2.72	132,500	$2.72

Options outstanding and exercisable by price range as of March 31, ~~2020~~2021 were as follows:

Outstanding Options

Average
Weighted

Exercisable Options

Range

Number

Remaining
Contractual
Life in Years

Number

Weighted
Average
Exercise Price

$0.05
  20,000
  0.77
  20,000
$0.05
$0.10
  220,000
  4.85
  220,000
$0.10
$0.11
  250,000
  3.76
  250,000
$0.11
$0.12
  200,000
  3.77
  200,000
$0.12
$0.27
  40,000
  4.76
  40,000
$0.27
$0.55
  100,000
  5.85
  100,000
$0.55






  830,000
  4.28
  830,000
$0.17

Outstanding Options		Average Weighted	Exercisable Options
Range	Number	Remaining Contractual Life in Years	Number	Weighted Average Exercise Price
$0.80	27,500	3.85	27,500	$0.80
$0.88	31,250	2.76	31,250	$0.88
$0.96	25,000	2.77	25,000	$0.96
$2.16	5,000	3.76	5,000	$2.16
$4.40	12,500	4.85	12,500	$4.40
$7.06	31,250	4.50	31,250	$7.06

	132,500	3.64	132,500	$2.72

Stock Warrants

In January 2019 we issued a warrant to purchase 1,000,000 shares of common stock to the CEO at an exercise price of $0.10 per share pursuant to an employment agreement. The warrant was valued at $89,654 and has a term of 5 years. We utilized the Black-Scholes model to fair value the warrant received by the CEO with the following assumptions: volatility, 143%; expected dividend yield, 0%; risk free interest rate, 2.58%; and a life of 5 years. The grant date fair value of each share of common stock underlying the warrant was $0.09.

In January 2019 we issued a warrant to purchase 250,000 shares of common stock to an employee at an exercise price of $0.12 per share. The warrant was valued at $21,931 and has a term of 3 years. We utilized the Black-Scholes model to fair value the warrant received by the employee with the following assumptions: volatility, 148%; expected dividend yield, 0%; risk free interest rate, 2.55%; and a life of 3 years. The grant date fair value of each share of common stock underlying the warrant was $0.09. ~~The value of the warrants was expensed in the fourth quarter of 2018 and included in accrued expenses at December 31, 2018.~~

In January 2020 we issued a warrant to purchase ~~1,250,000~~156,250 shares of common stock to ~~the CEO~~our Chief Executive Officer at an exercise price of ~~$0.15~~$1.20 per share pursuant to an employment agreement. The warrant was valued at $164,201 and has a term of 5 years. We utilized the Black-Scholes model to fair value the warrant received by ~~the CEO~~our Chief Executive Officer with the following assumptions: volatility, 136%; expected dividend yield, 0%; risk free interest rate, 1.64%; and a life of 5 years. The grant date fair value of each share of common stock underlying the warrant was ~~$0.13.~~$1.04.

In January 2020 we issued a warrant to purchase ~~41,667~~5,208 shares of common stock to an employee at an exercise price of ~~$0.12~~$0.96 per share. The warrant was valued at $3,594 and has a term of 5 years. We utilized the Black-Scholes model to fair value the warrant received by the employee with the following assumptions: volatility, 135%; expected dividend yield, 0%; risk free interest rate, 1.58%; and a life of 5 years. The grant date fair value of each share of common stock underlying the warrant was ~~$0.09.~~$0.72. The value of the warrants was expensed in the fourth quarter of 2019 and included in accrued expenses at December 31, 2019.

In February 2020 we issued a warrant to purchase ~~150,000~~18,750 shares of common stock to an employee at an exercise price of ~~$0.15~~$1.20 per share. The warrant was valued at $18,571 and has a term of 3 years. We utilized the Black-Scholes model to fair value the warrant received by the employee with the following assumptions: volatility, 155%; expected dividend yield, 0%; risk free interest rate, 1.64%; and a life of 3 years. The grant date fair value of each share of common stock underlying the warrant was ~~$0.12.~~$0.96.

On February 11, 2021, we agreed to amend (the “Warrant Amendment”) the warrant to purchase 125,000 shares of TOMI common stock, par value $0.01 (the “Common Stock”), issued by TOMI to Dr. Halden S. Shane, TOMI’s Chief Executive Officer and a director on TOMI’s board of directors, on February 11, 2014 (the “Warrant”), to provide TOMI an option to repurchase the Warrant from Dr. Shane at a negotiated price. In connection with the Warrant Amendment, TOMI repurchased the warrant from Dr. Shane (the “Repurchase”) for an aggregate cash consideration of $314,500, representing a 15% discount of the net exercise cash value of the Warrant, which was calculated using the closing price of the Common Stock on the Nasdaq on February 11, 2021 of $5.36, less the exercise price of the warrants in the amount of $2.40. On the same date, the Warrant Amendment and the Repurchase was considered, approved and adopted by a disinterested majority of TOMI’s board of directors. The $314,500 charge in connection with the warrant amendment has been included in General and Administrative expenses for the three months ended March 31, 2021.

The following table summarizes the outstanding common stock warrants as of March 31, ~~2020~~2021 and December 31, ~~2019:~~2020:

	March 31, 2021 (Unaudited)		December 31, 2020
	Number of Warrants	Weighted Average Exercise Price	Number of Warrants	Weighted Average Exercise Price
Outstanding, beginning of period	2,049,133	$2.55	2,155,065	$3.12
Granted	-	-	585,447	4.97
Exercised	-	-	(76,796)	(2.77)
Expired	(168,750)	(2.84)	(614,583)	(6.40)
Outstanding, end of period	1,880,383	$2.66	2,049,133	$2.55

March 31, 2020
(Unaudited)

December 31, 2019

Number of Warrants

Weighted Average Exercise Price

Number of Warrants

Weighted Average Exercise Price

Outstanding, beginning of period
  17,240,523
$0.39
  26,550,611
$0.34
Granted
  1,441,667
  0.12
  1,300,000
  0.11
Exercised
  (83,333)
  (0.69)
  -
  -
Expired
  (1,799,999)
  (0.47)
  (10,610,088)
  (0.23)
Outstanding, end of period
  16,798,858
$0.36
  17,240,523
$0.39

Warrants outstanding and exercisable by price range as of March 31, ~~2020~~2021 were as follows:

Outstanding Warrants

Exercisable Warrants

Exercise Price

Number

Average Weighted
Remaining Contractual
Life in Years

Number

Weighted Average
Exercise Price

$0.08
  250,000
  3.65
  250,000
$0.08
$0.10
  1,265,000
  3.51
  1,265,000
$0.10
$0.12
  3,791,667
  2.69
  3,791,667
$0.12
$0.14
  50,000
  4.05
  50,000
$0.14
$0.15
  1,400,000
  4.63
  1,400,000
$0.15
$0.17
  10,000
  2.57
  10,000
$0.17
$0.27
  250,000
  1.75
  250,000
$0.27
$0.29
  4,615,525
  1.91
  4,615,525
$0.29
$0.30
  1,200,000
  0.89
  1,200,000
$0.30
$0.32
  250,000
  1.50
  250,000
$0.32
$0.42
  250,000
  1.25
  250,000
$0.42
$0.50
  250,000
  1.00
  250,000
$0.50
$0.55
  100,000
  0.83
  100,000
$0.55
$0.69
  116,666
  0.10
  116,666
$0.69
$1.00
  3,000,000
  0.09
  3,000,000
$1.00

  16,798,858
  2.01
  16,798,858
$0.36

Outstanding Warrants			Exercisable Warrants
Exercise Price	Number	Average Weighted Remaining Contractual Life in Years	Number	Weighted Average Exercise Price
$0.64	31,250	2.65	31,250	$0.64
$0.80	158,125	2.51	158,125	$0.80
$0.96	473,958	1.69	473,958	$0.96
$1.12	6,250	3.05	6,250	$1.12
$1.20	175,000	3.63	175,000	$1.20
$1.36	1,250	1.57	1,250	$1.36
$2.16	31,250	0.75	31,250	$2.16
$2.32	523,061	0.91	523,061	$2.32
$2.40	12,500	0.50	12,500	$2.40
$2.56	31,250	0.50	31,250	$2.56
$3.36	31,250	0.25	31,250	$3.36
$4.00	28,750	4.35	28,750	$4.00
$6.95	375,000	9.50	375,000	$6.95
$8.40	1,488	2.38	1,488	$8.40
	1,880,383	3.35	1,880,383	$2.66

There were no unvested warrants outstanding as of March 31, ~~2020.~~2021.

NOTE 11. COMMITMENTS AND CONTINGENCIES

Legal Contingencies

We may become a party to litigation in the normal course of business. In the opinion of management, there are no legal matters involving us that would have a material adverse effect upon our financial condition, results of operations or cash flows. In addition, from time to time, we may have to file claims against parties that infringe on our intellectual property.

Product Liability

As of March 31, ~~2020,~~2021 and December 31, ~~2019,~~2020, there were no claims against us for product liability.

SARS CoV-2 coronavirus

On March 11, 2020 the World Health Organization declared the SARS CoV-2 coronavirus a global pandemic and recommended containment and mitigation measures worldwide. We ~~are monitoring this closely. We~~ have been identified as an essential disinfectant and decontamination vendor by various agencies and countries. Our operations being essential have been materially affected by the coronavirus outbreak to ~~date, as demand for our product and services is increasing.~~date. The uncertain nature of its spread globally may or may not impact our business operations resulting from quarantines of employees, customers and suppliers as well as potential travel restrictions in areas affected or may be affected in the future.

NOTE 12. CONTRACTS AND AGREEMENTS

Executive Agreements

Halden S. Shane

On September 22, 2020, we entered intoa three year employment agreement with Dr. Shane, effective October 1, 2020. The agreement provides for a base annual salary of $500,000. The agreement also provides for a signing bonus of 375,000 warrants. Dr. Shane is also entitled to a cash performance bonus and an annual issuance of an option to purchase 31,250 shares of common stock from the 2016 Plan at the discretion of the Board. The agreement also provides that we will reimburse Dr. Shane for the expenses associated with the use of an automobile up to $750 a month. The term of the agreement is three years.

In the event Dr. Shane is terminated as CEO as a result of a change in control, Dr. Shane will be entitled to a lump sum payment of two years’ salary at the time of such termination.

The Board may terminate Dr. Shane for cause by written notification to Dr. Shane; provided, however, that no termination for cause will be effective unless Dr. Shane has been provided with prior written notice and opportunity for remedial action and fails to remedy within 30 days thereof, in the event of a termination by the Company (i) by reason of willful dishonesty towards, fraud upon, or deliberate injury or attempted injury to, the Company, (ii) by reason of material breach of his employment agreement and (iii) by reason of gross negligence or intentional misconduct with respect to the performance of duties under the agreement. Upon termination for cause, Dr. Shane will be immediately paid an amount equal to his gross salary. The Board may terminate Dr. Shane other than for cause at any time upon giving notice to Dr. Shane. Upon such termination, Dr. Shane will be immediately paid an amount equal to his gross salary.

Elissa J. Shane

On October 1, 2020, we entered into an employment agreement with Elissa J. Shane, effective October 1, 2020. Pursuant to her employment agreement, Ms. Shane will receive an annual base salary of at least $270,000, subject to annual review and discretionary increase by the Compensation Committee of the Board. Ms. Shane is eligible to receive an annual cash bonus and other annual incentive compensation. The agreement originally provided for a grant of 93,750 warrants. Additionally, in connection with the execution of her employment agreement, on October 1, 2020, we issued Ms. Shane a warrant to purchase 93,750 shares of Common Stock at an exercise price of $6.17 per share. These provisions were subsequently amended to provide for the issuance to Ms. Shane of 31,250 options from the 2016 Equity Plan at the closing price of $7.06 on the date of grant in lieu of the warrant grant and the 93,750 warrants were cancelled. Ms. Shane acknowledged that the 31,250 options were in full consideration of the amount she was entitled to under the agreement. Her employment agreement also provides that we will reimburse Ms. Shane for reasonable and necessary business and entertainment expenses that she incurs in performing her duties. During the term of her employment, Ms. Shane will also be entitled to up to four weeks of paid vacation time annually, which will accrue up to six weeks, and to participate in our benefit plans and programs, including but not limited to all group health, life, disability and retirement plans. Ms. Shane is also entitled to the sum of $1,000 per month as a vehicle allowance. The initial term of her employment agreement is three years, which may be automatically extended for successive one-year terms, unless either party provides the other with 120 days’ prior written notice of its intent to terminate the agreement.

In the event Ms. Shane is terminated as COO as a result of a change in control, Ms. Shane will be entitled to a lump sum payment of one and a half years’ salary at the time of such termination.

Agreements with Directors

In December 2017, we increased the annual ~~board~~ fee to ~~directors~~the members of our Board to $40,000, to be paid in cash on a quarterly basis, with the exception of the audit committee chairperson, whose annual fee we increased to $45,000, also to be paid in cash on a quarterly basis. Director compensation also includes the annual issuance of our common stock.

For the three months ended March 31, ~~2019, we issued an aggregate of 400,000 shares of common stock that were valued at $44,000 to members of our board of directors.~~

~~For the three months ended March 31,~~ 2020, we issued an aggregate of ~~400,000~~50,000 shares of common stock that were valued at $48,000 to members of our ~~board~~Board.

For the three months ended March 31, 2021, we issued an aggregate of ~~directors.~~50,000 shares of common stock that were valued at $228,000 to members of our Board.

Manufacturing Agreement

In June 2020 we entered into a manufacturing agreement with Planet Innovation Products, Pty Ltd (“PI”). The agreement does not provide for any minimum purchase commitments and is for a term of three years. The agreement also provides for a warranty against product defects.

Cloud Computing Service Contract

In May 2020 we entered into an agreement for a cloud computing service contract. The contract provides for annual payments in the amount of $30,409 and has a term of 5 years.Approximate minimum payments under the contract are as follows:

Year Ended	Amount
April 1 – December 31, 2021	$18,000
December 31, 2022	30,000
December 31, 2023	30,000
December 31, 2024	30,000
December 31, 2025	15,000
	$123,000

Other Agreements

~~In June 2015, we launched the~~ TOMI Service Network (“TSN”)~~. The TSN~~ is a national service network composed of existing full-service restoration industry specialists that have entered initially into licensing agreements with us to become Primary Service Providers (“PSPs”). The licensing agreements ~~grant~~originally granted protected territories to PSPs to perform services using our SteraMist® platform of products and also provide for potential job referrals to PSPs whereby we are entitled to referral fees. Additionally, the agreement provides for commissions due to PSPs for equipment and solution sales they facilitate to other service providers in their respective territories. As part of these agreements, we are obligated to provide to the PSPs various training, ongoing support and facilitate a referral network call center. As of March 31, ~~2020,~~2021, we ~~had entered into 140 licensing agreements~~have 199 network companies in ~~connection with the launch of the~~ TSN. ~~The licensing agreements contain fixed price minimum equipment and solution orders based on the population of the territories granted pursuant to the licensing agreements.~~ The nature and terms of our TSN agreements may represent multiple deliverable arrangements. Each of the deliverables in these arrangements typically represent a separate unit of accounting. ~~As of January 1, 2020, we have removed the~~There is no exclusivity ~~portion of~~in our ~~service partner company agreements~~TSN network.

NOTE 13. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

~~Accrued expenses and other current liabilities consisted of the following at:~~

Accrued expenses and other current liabilities consisted of the following at:			Accrued expenses and other current liabilities consisted of the following at:

	March 31, 2020 (Unaudited)	December 31, 2019	March 31, 2021 (Unaudited)	December 31, 2020
Commissions	$237,466	$112,102	$158,076	$151,709
Payroll and related costs	224,752	167,689	208,511	84,000
Director fees	41,250		41,250
Sales Tax Payable	27,810	21,814	7,009	9,784
Income Taxes Payable (Note 16)			77,000
Accrued warranty (Note 14)	60,000	30,000	68,000
Other accrued expenses	64,458	77,257	69,951	70,106
Total	$655,736	$450,112	$629,797	$501,849

NOTE 14. ACCRUED WARRANTY

Our ~~manufacturer assumes~~manufacturers assume the warranty against product defects ~~for one year~~ from ~~the~~date of sale, ~~to customers,~~ which we extend to our customers upon sale of the product. We assume responsibility for product reliability and results. The warranty is generally limited to a refund of the original purchase price of the product or a replacement part. We estimate warranty costs based on historical warranty claim experience.

The following table presents warranty reserve activities at:

	March 31, 2020 (Unaudited)	December 31, 2019	March 31, 2021 (Unaudited)	December 31, 2020
Beginning accrued warranty costs	$30,000		$68,000	$30,000
Provision for warranty expense	31,864	2,609	1,292	101,041
Settlement of warranty claims	(1,864)	(2,609)	(1,292)	(63,041)
Ending accrued warranty costs	$60,000	$30,000	$68,000

NOTE 15. ~~CUSTOMER DEPOSITS~~LOAN PAYABLE

AtOn April 21, 2020, we received $410,700 in loan funding from the Paycheck Protection Program (the "PPP") established pursuant to the recently enacted Coronavirus Aid, Relief, and Economic Security Act of 2020 (the "CARES Act") and administered by the U.S. Small Business Administration ("SBA"). The unsecured loan (the "PPP Loan") is evidenced by a promissory note of the Company, dated April 21, 2020 (the "Note") in the principal amount of $410,700 with City National Bank (the "Bank"), the lender. Interest expense for the three months ended March 31, ~~2020~~2021 was $1,035.

Under the terms of the Note and ~~December~~the PPP Loan, interest accrues on the outstanding principal at the rate of 1.0% per annum. The term of the Note is two years, though it may be payable sooner in connection with an event of default under the Note.

In March of 2021, the loan forgiveness application was filed with our bank and was pending approval as of March 31, 2019, there were customer deposits of $1,017,533 and $0, respectively on future equipment orders. In the first quarter of 2020, we began requiring a 50% customer deposit on placing most orders and payment in full prior to delivery on most orders to mitigate credit risk and to improve liquidity.2021.

NOTE 16. INCOME TAXES

For the three months ended March 31, ~~2020~~2021 and ~~2019,~~2020, our provision for income tax was $0. Deferred income tax assets and liabilities are determined based on differences between the financial statement reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws in effect when the differences are expected to reverse. The measurement of deferred income tax assets is reduced, if necessary, by a valuation allowance for any tax benefits, which are, on a more likely than not basis, not expected to be realized in accordance with ASC guidance for income taxes. As of March 31, ~~2020~~2021 and December 31, ~~2019,~~2020, we recorded a valuation allowance of ~~$4,743,000~~$3,953,000 and ~~$5,580,000,~~$3,530,000, respectively for the portion of the deferred tax assets that we do not expect to be realized. The valuation allowance on our net deferred taxes decreased by $837,000 during the three months ended March 31, 2020, primarily due to U.S. deferred tax assets incurred in the current period that could be realized. Management believes that based on the available information, it is more likely than not that the remaining U.S. deferred tax assets will not be realized, such that a valuation allowance is required against U.S. deferred tax assets. The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted.

NOTE 17. CUSTOMER CONCENTRATION

~~The Company~~We had ~~certain customers~~no customers/distributor whose revenue individually represented 10% or more of ~~the Company’s~~our total revenue ~~or whose accounts receivable balances individually represented 10% or more of the Company’s accounts receivable.~~

~~As of March 31, 2020, one customer accounted~~ for ~~12% of our accounts receivable. As of December 31, 2019, three customers accounted for 37% of accounts receivable~~.

~~For~~ the three months ended March 31, ~~2020, sales made to one international customer /~~ 2021. One customer/distributor accounted for 31% of net ~~revenue. For~~revenue for the three months ended March 31, ~~2019, two customers~~2020. We had three customers/distributors that accounted for ~~45%~~38% of ~~net revenue.~~accounts receivable as of March 31, 2021. Three customers/distributors accounted for 36% of accounts receivable as of December 31, 2020.

NOTE 18. SUBSEQUENT EVENTS

~~On April 21, 2020, TOMI Environmental Solutions, Inc. (the "Company") received $410,700 in loan funding from~~The Company has evaluated subsequent events through the ~~Paycheck Protection Program (the "PPP") established pursuant~~date the financial statements were issued and up to the ~~recently enacted Coronavirus Aid, Relief, and Economic Security Act~~time of ~~2020 (the "CARES Act") and administered by the U.S. Small Business Administration ("SBA"). The unsecured loan (the "PPP Loan") is evidenced by a promissory note~~filing of the ~~Company, dated April 21, 2020 (the "Note") in~~financial statements with the ~~principal amount of $410,700 with City National Bank (the "Bank"), the lender.~~

Under the terms of the Note and the PPP Loan, interest accrues on the outstanding principal at the rate of 1.0% per annum. The term of the Note is two years, though it may be payable sooner in connection with an event of default under the Note. To the extent the loan amount is not forgiven under the PPP, the Company will be obligated to make equal monthly payments of principal and interest beginning on the date that is seven months from the date of the Note, until the maturity date.

In April 2020 the company issued 100,000 warrants to its Chief Executive Officer, 50,000 warrants to its Chief Operating Officer and 50,000 warrants to its Chief Financial Officer, all exercisable at $0.50 per share.

~~In May 2020, 3,116,666 warrants expired reducing the number of outstanding warrants to 13,912,192~~SEC. There were no reportable subsequent events.

I~~tem~~Item 2. ~~Management’s~~Management’s Discussion and Analysis of Financial Condition and Results of Operations.

~~You should read~~This section and other parts of this Quarterly Report on Form 10-Q (“Form 10-Q”) contain forward-looking statements, within the ~~following discussion~~meaning of ~~our financial condition~~the Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. For example, statements in this Form 10-Q regarding the potential future impact of the COVID-19 pandemic on the Company’s business and results of operations ~~in conjunction with the condensed consolidated financial~~are forward-looking statements. Forward-looking statements can also be identified by words such as “future,” “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “will,” “would,” “could,” “can,” “may,” and similar terms. Forward-looking statements are not guaranteeing future performance and the ~~related notes included elsewhere~~Company’s actual results may differ significantly from the results discussed in ~~this Form 10-Q and with our audited consolidated financial statements included~~the forward-looking statements. Factors that might cause such differences include, but are not limited to, those discussed in ~~our~~Part I, Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2019,~~2020 (the “2020 Form 10-K”) under the heading “Risk Factors.” The Company assumes no obligation to revise or update any forward-looking statements for any reason, except as required by law.

Unless otherwise stated, all information presented herein is based on the Company’s fiscal calendar, and references to particular years, quarters, months or periods refer to the Company’s fiscal years ended in December and the associated quarters, months and periods of those fiscal years. Each of the terms the “Company” and “TOMI” as used herein refers collectively to TOMI Environmental Solutions, Inc. unless otherwise stated.

The following discussion should be read in conjunction with the 2020 Form 10-K filed with the ~~SEC. In addition to our historical~~U.S. Securities and Exchange Commission (the “SEC”) and the condensed consolidated financial statements and accompanying notes included in Part I, Item 1 of this Form 10-Q.

Available Information

The Company periodically provides certain information for investors on its corporate website, www.tomimist.com, and its investor relations page of its website, www.investor.tomimist.com. This includes press releases and other information about financial performance, information on corporate governance and details related to the ~~following discussion contains forward-looking statements that reflect our plans, estimates,~~Company��s annual meeting of shareholders. The information contained on the websites and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewherereferenced in this Form 10-Q is not incorporated by reference into this filing. Further, the Company’s references to website URLs are intended to be inactive textual references only.

Quarterly Highlights

Business Update

As we exited 2020 and began 2021, the Company is re-focusing on its core customers and markets. COVID saw an increase and introduction to a new set of customers, which was beneficial to the Company as it brought awareness to product, offerings and opened the door to a customer base at a very rapid pace. These customers were initially looking for products that would aid in their ability to keep their businesses open. As the quarantines continued and more businesses were closed the Company saw a slowdown in demand for products from these new customers. In addition, our existing life sciences customers closed early in COVID and remained closed into 2021. We expect the quarantines to remain into the first half of 2021. As our core customers in Life Sciences, Commercial and Healthcare are slowly re-opening, we expect to see increased demand for our products and services in the latter half of 2021. Our focus in 2021 will be on working with our customers as they return to work.

Due to the business quarantine shut downs, our first quarter 2021 revenues are down from the early pandemic high of 2020. To address the return to work with our customers, the Company is building its sales team. We believe it will take time to get the new team trained and fully operational.

In addition to building the team, the Company is addressing the needs of our customers for a more mobile and lighter weight product by introducing the SteraPak. Many of our customers are waiting for the release instead of purchasing our existing products. New product and service introductions can significantly impact net sales, cost of sales and operating expenses. The timing of product introductions can also impact the Company’s net sales to its indirect distribution channels as these channels are filled with new inventory following a product launch, and channel inventory of an older product often declines as the launch of a newer product approaches. Net sales can also be affected when consumers and distributors anticipate a product introduction domestically and internationally. Despite lower revenues for the quarter, the Company and its divisions remain resilient and currently expect to meet the targeted 2021 annual revenue goals.

COVID-19 Update

The COVID-19 pandemic has prompted governments and businesses to take unprecedented measures, such as restrictions on travel and business operations, temporary closures of businesses, and quarantines and shelter-in-place orders. This has significantly curtailed global economic activities and has impacted our operations, particularly international sales.

During the first quarter of 2021, aspects of the Company’s business continued to be affected significantly by the COVID-19 pandemic. Some of the Company’s major customers in the Hospital/healthcare, Life Science and channel partners temporarily closed at various times, while the vast majority of our old and new pipeline clients’ employees have transitioned to working remotely. The closure and/or such customers working remotely placed a halt on many of our ongoing long-term projects that were set to close in late 2020 and early 2021. These projects and the addition of new projects at very early stages have resumed during the second quarter with a few planned to be completed by end of 2021. These divisions have or are starting to reopen during the first part of the second quarter. Further, we have recently experienced an increase in capital equipment sales in the Life Sciences during the second quarter of 2021 as pharmaceuticals, research universities, vivariums, and government agencies are gradually returning to work and interested in purchasing our equipment.

Travel restrictions and the transition to our newly formed sales operation and sales team has further affected our domestic and international sales in the short term. Due to the nature of our technology, industry knowledge, and the amount of time required for onboarding new sales teams, including new Independent Manufacturing Representatives (IMRs), it takes time to build a pipeline and become fully operational in the sales role. We expect a more positive impact from these efforts on our financial results by the second half of 2021.

Prior to the pandemic, in 2019, the Company had revenues of approximately $6,000,000, and our 2020 business plan anticipated substantial growth in 2020. While we exceeded our budget, the pandemic did not allow us to implement our initiatives to generate the sustained growth beyond the pandemic. As our historical consistent verticals return to work, we are reinstating live and in-person demonstrations of our products for these verticals/industries, in addition to resuming long-term ongoing profitable projects, which we believe will have a positive impact on our efforts to generate new sales. With the anticipated launch of our new product lines (SteraPak, SteraBox, SteraBot), we expect the rate of revenue growth will accelerate in the second half of 2021. These new products were designed and will be launched based on the feedback of our customers for alternative delivery systems and commercial uses for the SteraMist products.

The second half of 2020 showed us that the world remained interested in the disinfection process. The potential customers who did not want to take the time to learn of proper disinfection protocols and the importance of SteraMist competitive advantages but made their purchasing decisions primarily based on price resulted in potential customers selecting a less expensive disinfection technology including electrostatic sprayers (ESS).

TOMI rapidly transformed its R&D department to produce a backpack, the SteraPak, with 6-log kill in seconds based on our proprietary BIT technology platform. Our SteraMist SteraPak is expected to hit the markets shortly. We are already taking and receiving pre-orders, and the interest is high across all markets.

The full extent of the future impact of the COVID-19 pandemic on the Company’s operational and financial performance is currently uncertain and will depend on many factors outside the Company’s control, including, without limitation, the timing, extent, trajectory and duration of the pandemic; the availability, distribution and effectiveness of vaccines; the imposition of protective public safety measures; and the impact of the pandemic on the global economy and demand for consumer products. Refer to Part ~~II,~~I, Item 1A of the 2020 Form 10-K under the heading “Risk ~~Factors.~~Factors,” for more information.

Overview

TOMI Environmental Solutions, Inc. (“TOMI”, “we” and “our”) is a global ~~provider~~bacteria decontamination and infectious disease control company, providing environmental solutions for indoor surface decontamination through the manufacturing, sales, service and licensing of ~~disinfection and decontamination essentials through~~ our ~~premier Binary Ionization Technology~~SteraMist® ~~(BIT~~™~~) platform, under which we manufacture, license, service and sell our SteraMist~~®brand of products, including SteraMist® BIT™, a low percentage (7.8%) hydrogen peroxide-based fog or ~~mist.~~mist that uses Binary Ionization Technology (BIT™).

~~TOMI’s~~Our SteraMist®is a patented technology that produces ionized Hydrogen Peroxide (iHP™) using cold plasma science created under a grant by the United States Defense Advanced Research Projects Agency (DARPA). ~~TOMI’s~~Our EPA registered BIT™ Solution is composed of a low concentration of hydrogen peroxide converted to iHP™ after passing the trade secret blended solution including its sole active ingredient of 7.8% hydrogen peroxide through an atmospheric cold plasma arc. The newly formed iHP™ fog and mist consists of submicron’s to 3-micron radical particles that are carried throughout the treatment area in a fog or mist moving with the same velocity and characteristics of a gas. This allows the ionized hydrogen peroxide fog or mist to affect all surfaces and air space throughout the targeted treatment area, over, above and beyond the ability of a manual cleaning processes. iHP™ damages pathogenic organisms through the oxidation of proteins, carbohydrates, and lipids. SteraMist® no-touch disinfection and or decontamination treat areas mechanically, causing cellular disruptions and/or dysfunctions resulting in a 6-log (99.9999%) and greater kill or inactivation of all pathogens in the treatment area.

Under the Federal Insecticide, Fungicide, and Rodenticide Act (“FIFRA”), we are required to register with the EPA and certain state regulatory authorities as a seller of disinfectants. In June 2015, SteraMist® ~~Binary Ionization Technology® allows~~BIT™was registered with the EPA as a ~~facility~~hospital-healthcare disinfectant and general broad-spectrum surface disinfectant for use as a misting/fogging agent. SteraMist®BIT™now holds EPA registrations (# 90150-2) for mold control, and air and surface remediation (# 90150-1). In February 2016, we expanded our label with the EPA to ~~have~~include ClostridiumdifficileSporesand MRSA, as well as the influenza (Avian) virus h1n1, which we believe has better positioned us to penetrate all industries including the biodefense and healthcare industry. In August 2017, our EPA label was further expanded to include efficacy against Salmonella and Norovirus. As of January 27, 2017, our technology is one of 53 of the EPA’s “Registered Antimicrobial Products Effective against ClostridiumdifficileSpores”, as published on the EPA’s K List. Further, in December 2017, SteraMist®was included in the EPA’s list G (Norovirus), L (Ebola) and M (Avian Flu). In March 2020, our EPA label was further amended to include Emerging Viral Pathogens claims, thus meeting the criteria against Enveloped viruses and Large Non-enveloped viruses and included on List N (Emerging Viral Pathogens including SARS-CoV-2).

SteraMist®BIT™brings to the world a ~~hospital-healthCare~~mechanical and automated method of cleaning using a game-changing technology and EPA registered ~~tool~~Hospital-HealthCare disinfectant providing an upgrade to existing disinfecting and ~~solution to replace manual~~ cleaning ~~technology, upgrade existing~~ protocols ~~and limit~~while limiting liability in a facility when it comes to resistant infectious pathogens. ~~SteraMist~~®We ~~BIT~~™~~is the first EPA registered solution and system combination on the market. BIT~~™~~is also listed on EPA’s List G, H, K, L, M and N for Norovirus, MRSA, C.diff, Ebola, Avian flu or Influenza and SARS-CoV-2 respectively.TOMI maintains~~maintain this registration in 50all fifty (50) states, Canada, and approximately 22thirty-five (35) other countries.

Markets

~~TOMI’s~~Our SteraMist® products are designed to address a wide spectrum of industries using ~~ionized Hydrogen Peroxide (iHP~~iHP™). Our operations ~~are organized into four~~consist of five main divisions based on our current target industries: ~~Hospital-Healthcare,~~Hospital-HealthCare, Life Sciences, TOMI Service Network (TSN), Food Safety and ~~Food Safety. In addition, TOMI is able to bring SteraMist~~®Commercial. ~~efficacy to each division through scheduled iHP~~® ~~Service in both routine and emergency capacities. SteraMist~~® ~~technology and iHP~~® ~~Service are available both domestically and internationally.~~

~~Products~~

We continue to offer our customers a wide range of innovative mobile products designed to be easily incorporated into their existing disinfection and decontamination procedures and protocols. Our newly soon to be released SteraPak will allow us to progress further into market share, specifically for our Hospital-HealthCare, TSN, and Commercial divisions. Additionally, we offer integrated facility equipment installations known as Custom Engineered Systems (CES), routine & emergency iHP™ Corporate Service, essential training packages, validations and qualifications, and onsite performance maintenance requests, – which are all profitable for our Life Sciences and expect to soon be profitable in our Food Safety division.

Each of these are structured to address the unique disinfection and decontamination needs of our customers ~~worldwide.~~worldwide regardless of industry requiring or requesting SteraMist®disinfection decontamination.

Divisions

Hospital-Healthcare

~~TOMI’s hospital-healthcare customer list continues to grow with the closing of every quarter. TOMI’s~~Our SteraMist® ~~Hospital Disinfection Cart, an all-in-one cart that houses our handheld point-and-spray~~line of products, specifically the SteraMist® Surface Unit and ~~accompanying supplies, continues to assist medical staff with emergency response and turnaround for new and established protocols. The~~ SteraMist® ~~Hospital~~Total Disinfection Cart are our main solutions to aid our Hospital-HealthCare customers in providing the quality of care and safety they provide to their patients by disinfecting patient and operating rooms, pharmacies, ambulances, and emergency environments in a hospital or healthcare facility. TOMI’s latest product, the SteraPak, further assists healthcare communities with an easy-to-use, cordless disinfection cart allows customers within the hospital-healthcare industry to address concerns of the cross-contamination of dangerous bacteria and viral pathogens in which some can lead to HAIs stemming from existing and emerging pathogens, as well as multiple drug resistant organisms (MDRO’s). SteraMist® ~~Technology allows~~solution, creating a manual cleaning protocol lasting 90 minutes to be reduced to 55 minutes, including the changing of bed linens, as confirmed by the Shield Study at UCLA. This mobile consolidation solution has resulted in remarkable results for facilities utilizing our technology. Previously published results of N95 mask disinfection efficacy were shortly followed by the official listing of SteraMist as a List N disinfectant against the SARS-CoV-2 Coronavirus.quicker turnaround time.

In the first quarter of 2021, we experienced an increase in sales to health system clients, including the expansion to our third Mercy hospital in Ohio, with a fourth Mercy facility seeking to implement SteraMist soon. We also received multiple purchase orders from Zimmer, a medical device company.

Our team of technicians and representatives train, maintain, and troubleshoot capital equipment throughout the world for our Hospital-HealthCare customers. As our Training and Implementation department expands, we expect continued growth in our Hospital-HealthCare division. The protocol development and onboarding for implementation in this division is critical. During 2020 the use of our SteraMist®in such campuses increased due to our comprehensive training for their day and night shift maintenance and housekeeping departments. By late 2021, we anticipate annual comparison case studies from many of these facilities who were onboarded in 2020, which may show lower transmission infection rates in COVID, ClostridiumdifficileSpores and overall, HAI cases.

Life Sciences

~~TOMI’s~~Our SteraMist®. Environment System, Custom Engineered ~~Solutions,~~Systems (CES), the SteraMist® Select Surface Unit, custom iHP™ implementation to decontamination chambers and cage washers, and our iHP™Corporate Service Division, are designed to be tailored to provide a complete room solution to address the regulatory inspections of disinfecting/decontaminating and Installation Qualification (IQ)-Operational Qualification (OQ)–Performance Qualification (PQ) validation processes within the life sciences industry.

The pandemic halted capital equipment and service sales in our Life Sciences division and its verticals. As operations reconvene for these verticals, we expect to see increased demand from this vertical. Long term ongoing projects and validations have resumed, along with proposals and interest for our CES permanent decontamination room. We will work with our customers to respond to their inquiries regarding CES. These are longer lead-time sales that can take months to design, build and implement. We expect these installations to have impact to our results in late 2021 and into 2022.

Further, post COVID pandemic has brought some attention to the SteraMist product line as our CES in Pfizer Missouri was recently showcased in a New York Times article as they featured their COVID vaccine processes. In addition, ~~TOMI has worked alongside many research universities and government agencies~~our iHP Corporate Service team treated one of four fill lines in a North Carolina pharmaceutical company that manufacturers one of the COVID vaccines, with the remaining three lines set to be decontaminated in the ~~effort~~future with SteraMist.

TOMI developed a new product which acts as a passthrough or small decontamination chamber, the SteraBox, to ~~test SteraMist efficacy on the disinfection~~sterilize small instruments quickly and re-use of N95 masks and other equivalent PPE, with results that indicate that the use of SteraMist iHP™ will not reduce mask efficacy, including on those containing 10% or less of cellulose. SteraMist has also been included in studies observing the effects of iHP disinfection on the reduction of ~~Syphacia obvelata~~ ~~pinworm ova presence in rodent cages, which indicated positive results.~~efficiently.

TOMI Service Network

The TOMI Service Network, or TSN, is an expansive network consisting of third-party professionals specializing in a wide array of disciplines who are exclusively licensed and trained to use the SteraMist® products. ~~TOMI sells, trains,~~We sell, train, and ~~services~~service a wide array of professional remediation companies in the use of SteraMist® through the TSN division. This allows for increased accessibility and brand awareness of ~~Binary Ionization Technology~~iHP®services to facilities in need of local routine and emergency disinfection and decontamination.

~~Many~~The TOMI Service Network (TSN) division experienced greater impact from the COVID-19 pandemic quarter over quarter than any other division. As stated above, the urgency of ~~these companies specialize~~becoming an essential business prompted an increase of demand for SteraMist disinfection by our customers who wished to remain in ~~mold remediation, treatment of water-damaged areas (including damage from CAT 1-3 water loss), fire damage, as well as professional specialists that are certified and practice~~operation in the ~~area~~first half of ~~forensic restoration. Currently,~~2020, and TSN members acquired and accumulated BIT Solution in anticipation of supply shortage. We believe that cleaning protocols have changed permanently due to the ~~TSN features~~COVID-19 pandemic, and our network will play a ~~number of professionals~~significant role in facilitating and maintaining these protocols throughout ~~both~~ the United States and ~~Canada,~~Canada. The urgency for emergency disinfection services may have declined, but the education and support of such services provided to our members by TOMI personnel provides us with ~~some utilizing~~an advantage to maintaining strong business relationships with these companies and their thousands of happy SteraMist® customers as ~~a standalone service and others incorporating SteraMist into their existing business models and methods.~~the world returns to the new normal.

As of March 31, 2021, we have 199 network companies in TSN. We expect our TSN division to onboard approximately 6 to 8 new TSN members per quarter. We also expect our SteraPak release to be an important factor for this market that will increase the new member onboarding number quarter over quarter moving forward.

Sales of BIT™ Solution make up a large amount of our consistent revenue stream, and members of the TOMI Service Network are a large portion of those recurring sales. As of January 1, 2020, we have removed the exclusivity portion of our service partner company agreements, allowing us to expand our network and further penetrate existing markets. The TSN network has grown significantly to date in 2020, with the total number of service providers currently at one hundred and sixty (160), which has expanded our network membership across forty-four (44) U.S. States and two (2) Canadian provinces. Currently, there are approximately 295 SteraMist® ~~units in the field across all members of TSN™.~~

Food Safety

~~As one of our newest targeted markets,~~ Food Safety presents significant potential as an opportunity for substantial growth with continued product research and compliance testing. With the food safety industry in North America coming under closer scrutiny with the implementation and enforcement of new and established guidelines, our consultants have submitted a request to expand our current labels to include a 1% acceptable concentration of hydrogen peroxide. This concentration has previously been approved by the USDA and FDA for direct food and crop application and will allow SteraMist®to expand use sites beyond food processing machinery, restaurants, and food contact areas to assist in compliance with the ~~newly-established~~newly established Food Safety Modernization Act guidelines set in place by the FDA, as well as the Safe Food for Canadians Act and Safe Food for Canadians Regulations in Canada.

TOMI continues to work with premium companies in testing and validating SteraMist®technology in the Food Safety and seed industries. In the first quarter of 2021, we have made progress in enhancing brand awareness and promoting and marketing in this division, as a majority of the Independent Marketing Representatives we onboarded recently belong to this division.

Commercial

Our Commercial division, which includes but is not limited to use sites such as aircraft, airports, police and fire, manufacturing companies, automobile, military, cruise ships, shipping ports, preschool education, primary ~~objective is~~and secondary schools, colleges including dormitories, all modes of public and private transportation, regulatory consulting agencies, retail, housing and recreation, and of course emergency preparedness for counties and cities to ~~prevent and/or minimize food decay without~~use SteraMist®throughout their community.

Quarter 1 of 2021 continued to bring interest to the ~~use of harsh chemicals that leave toxic residues, which could create~~marketplace for these industries and interest in SteraMist disinfection as a ~~lucrative opportunity~~solution remains high. We expect the SteraPak to ~~supplement or replace current pesticides and fungicides currently being used by industry leaders.~~be a game changer in growth for this division.

Business Highlights and Recent Events

~~SARS CoV-2 coronavirus~~.Customers:

~~On March 11, 2020 the World Health Organization declared the~~ ~~SARS CoV-2 coronavirus~~ ~~a global pandemic and recommended containment and mitigation measures worldwide~~. We have been identified as a disinfectant and decontamination vendor by various agencies and countries. We have been working relentlessly with organizations to address the concerns and provide solutions for disinfecting and decontamination of the SARS CoV-2 coronavirus. The outbreak has increased the demand for TOMI products and services. We anticipate that the outbreak will change requirements and processes for decontamination and disinfecting worldwide, of which SteraMist will be a solution. We are working with our existing and new customers to develop and/or upgrade their existing processes and requirements for decontamination and disinfecting.

We have been addressing the increased demand for our products as follows: (i) cooperation of our supply chain to expedite product, (ii) increase our staff to be able to receive and ship orders to meet customer timelines (iii) increase our customer service support to answer questions and solve issues and (iv) working with our Tomi service network to ensure that resources are deployed in a timely manner. In addition, we increased our production capacity and will be entering into an agreement with a second vendor to build our SteraMist products.

~~Customers:~~

~~In response to the increased demand due to the global pandemic outbreak, our customer list grew substantially on the first quarter~~.Globally, we have added eighty-one (81) new customers across all our divisions for the three months ended March 31, 2020. This represents a six hundred and eight-six (686%) percent increase over the first quarter of 2019. We anticipate that the new customers will continue to order products beyond the outbreak.

Our TSN division added thirty-six (36) new service providers for the three months ended March 31, 2020, an increase of 1700% compared to the first quarter of 2019. TSN was the key division to address the demand for decontamination and disinfecting services during the outbreak. We anticipate that TSN will continue to service the new customers as a result of the outbreak, as customers update their requirements and processes with these services.

~~Our Hospital-Healthcare division added eighteen (18) new facilities for the three months ended March 31, 2020 which represents 800% increase compared to the prior year period.~~

~~Our Life Sciences customer base showed continued growth with the addition of eighteen (18)~~approximately thirteen (13) new customers for the three months ended March 31, 2021. In the short term, we expect to see healthy demand for the SteraMist®products and services. While the initial outbreak caused a surge in demand for the SteraMist®, we expect that such demand for our products and services will continue and we are building a team to address the post COVID-19 pandemic market opportunities.

Revenues:

We experienced a decline in our revenue for the three months ended March 31, 2021 when compared to the same quarter in the prior year due to a significant increase of demand caused by the onset of the COVID-19 pandemic in March 2020. We were positioned well to respond to the pandemic related spike in demand due to our inventory levels and increased production capacity which led to substantial revenue growth in the first and second quarter of 2020. However, during of the second half of 2020 and early 2021, many of our established vertical clients were closed or required to reduce or suspend their business operations. The markets that were negatively affected were our life sciences clients that were nonessential, University and privately owned vivarium labs, and many nonessential pharmaceutical research companies globally. In addition, the healthcare industryhas shifted virtually all of its focus and resources in response to the pandemic and therefore reduced substantially their elective surgical and clinical related services, resulting in limited non-essential onsite personnel. These trends made it more difficult for us to demo our equipment and execute our sales and marketing strategies. In addition, our customers have limited budgets for newer technologies. We anticipate that the availability of significant federal funds to our customers for pandemic preparedness should assist them in purchasing our products.

As many industrial companies are reducing R&D and capital expenditures spending due to the economic impact of the pandemic, we are moving ahead with many new products in development. In 2021, we intend to spend more on capital expenditures (CapEx) and operating expenditures (OpEx) including development of new products, services and process technologies to sharpen our competitive advantage. In addition, we will expand our commercial service location to meet the expanding needs of our customers.

We believe that we possess the best technologies in the world in the disinfection and decontamination space. This ~~represents~~pandemic has provided us with the confidence to develop a ~~533% increase~~clear strategy to manufacture what may be our best product portfolio to date. In addition, we continue to move our BIT technology closer to becoming the standard in disinfection and decontamination globally. This should lead to a greater market share, increased profitability and capability strength.

The second half of 2020 showed us that our customers wanted a lower cost disinfection device like electrostatic sprayers (ESS), even if it provides the end-user with less efficacy and the potential of causing damage to its personal property and delicate equipment which were dangerous and causing explosions with many resulting in fires.

To respond to our customer demands of a lower cost and more versatile product, we developed a Backpack unit that will possess our award winning 6-log and above kill technology and speed without the damage to space and materials. We expect our backpack to be competitively priced and open SteraMist to the largest cleaning market in the world-members of ISSA (International Sanitary Supply Association) and its divisions IEHA (Integrated Environment and Health Assessment) and EMEA (Europe, Middle East & Africa). These organizations have historically been price conscious and were resistant early on to our SteraMist pricing of our professional decontamination equipment (SteraMist Surface and Environment Unit). We plan on introducing our new innovative backpack globally in the second or early third quarter 2021.

We believe that disinfection will be a line item on all companies’ budgets going forward whether private, public or government. Dangerous pathogens still exist “Disease X” and will exist long after we recover from this pandemic. While the United States and most of the world is currently recovering from the SARS CoV-2 coronavirus outbreak there are many pathogens which are respiratory in nature that are still a looming threat, these cases are occurring globally to this day. SteraMist can mitigate and reduce the impact of the next pandemic as it has already proven during the outbreaks of Ebola, MERS and recently with SARS CoV-2 pandemic. The need for a speedy comprehensive mechanical disinfectant like SteraMist cannot be stressed enough and should be included as the new norm of cleaning. With all the unknown viruses and their variants in the world, preparedness is the most important measure to ensure your family and business survives.

Total revenue for the three months ended March 31, 2021 and 2020, was $2,073,000 and $7,053,000, respectively, representing a decrease of $4,980,000, or 71% compared to the same prior year period.

~~Revenues:~~

Total revenue for the three months ended March 31, 2020 and 2019, was approximately $7,053,000 and $1,253,000, respectively, representing an increase of $5,800,000, or 463% compared to the same prior year period. The increase in revenue was attributable to increased global demand for disinfection and infectious disease control products in response to the SARS CoV-2 coronavirus ~~global pandemic. In the first quarter we saw significant demand for our product with our Hospital-Healthcare and TSN sales as a result of the~~SteraMist® ~~SARS CoV-2 coronavirus~~ global pandemic. We expect the revenue to continue to grow as our customers update their requirements, processes and procedures to include decontamination and disinfecting services into their regular routines.

~~SteraMist~~ product-based revenues for the three months ended March 31, 2021 and 2020, were $1,661,000 and ~~2019, were approximately~~ $6,638,000, ~~and $1,029,000,~~ representing ~~an increase~~a decrease of ~~$5,609,000~~$4,977,000 or ~~545%~~75% when compared to the same prior year period. The growth is attributable to increased mobile equipment orders and solution orders from our existing customer base as well as our new customers. We expect solution orders to continue to grow as the new and existing customers adopt new processes and requirements for decontamination and disinfecting services. We cannot determine the frequency or quantities at this time, as the industry is rapidly evolving.

Our service-based revenue for the three months ended March 31, 2021 and 2020, was $412,000 and ~~2019, was approximately~~ $415,000, ~~and $224,000,~~ respectively, representing a year over year ~~increase~~decrease of ~~85%~~1%. ~~The increase in our service-based revenue was attributable to higher training sales recorded in the first quarter to onboard new customers.~~

Our domestic revenue for the three months ended March 31, 2021 and 2020, was $1,804,000 and ~~2019 was~~ $3,569,000, ~~and $1,136,000,~~ respectively, ~~an increase~~a decrease of ~~$2,433,000,~~$1,765,000, or ~~214%~~49% when compared to the same prior year period. ~~The increase was primarily due to the growth in our TSN network and in our Hospital-Healthcare customers.~~

Internationally, our revenue for the three months ended March 31, ~~2020~~2021 and ~~2019,~~2020, was approximately ~~$3,484,000~~$269,000 and ~~$117,000,~~$3,484,000, respectively, representing ~~an increase~~a decrease of ~~$3,367,000~~$3,215,000 or ~~2,878% when compared to the first quarter of 2019. The increase in our international revenue was attributable to the increased use and expansion of our SteraMist~~® line of products in Canada, Europe, Asia and the Middle East. We expect our international revenue to continue to grow as more countries adopt our products and services as well as change their decontamination and disinfecting requirements.92%.

~~Our Hospital-Healthcare revenues grew by approximately 6,000% in the first quarter of 2020 when compared to the same prior year period. The growth was primarily attributable to the~~ ~~significant demand for our product as a result of the~~ ~~SARS CoV-2 coronavirus~~ ~~global pandemic~~. We anticipate continued growth in this sector as hospital-healthcare facilities review and adopt new processes and technologies to address current and future outbreaks. We cannot predict the frequency or volume of orders as the world’s response to decontamination and disinfecting is evolving. However, we anticipate continued growth moving into 2020.

We expanded TSN membership and grew TSN revenue in the first quarter of 2020 by 727% when compared to the same prior year period. The growth in revenue was largely due to the increased demand for decontamination technologies in response to the SARS CoV-2 coronavirus ~~a global pandemic.~~

2021 Events:

~~Following are the significant events during the first quarter 2020:~~

●

~~January 29, 2020 – TOMI SteraMist~~® ~~prepared to deploy to fight SARS CoV-2 coronavirus.~~

●

~~February 4, 2020 - TOMI Receives China CDC Registration Making SteraMist~~® ~~the Disinfection Industry Standard in China~~

●

~~February 27, 2020 - SteraMist~~® ~~Takes the Fight to the SARS CoV-2 coronavirus. Worldwide - China, Hong Kong, Thailand, Singapore, Israel and the United Kingdom~~

●

~~March 2, 2020 - SteraMist~~® ~~Declared Official Decontamination Technology of Seoul City Metropolitan Transit Systems~~

●

~~March 10, 2020 - SteraMist~~® ~~is Mobilized to Aid in the Control SARS-CoV-2 coronavirus in Daegu-Kyungbuk Province, South Korea~~

●

~~March 11, 2020 - SteraMist~~® ~~is Prepared to Fight SARS-CoV-2 coronavirus in Thailand~~

●

~~March 11, 2020~~ – ~~The World Health Organization declared the~~ ~~SARS CoV-2 coronavirus~~ ~~a global pandemic and recommended containment and mitigation measures worldwide~~. We have been identified as a disinfectant and decontamination vendor by various agencies and countries, ensuring TOMI’s continued operation through established federal and state quarantine measures while simultaneously increasing the demand for TOMI products and services. We have been working relentlessly with organizations to address the concerns and provide disinfection and decontamination solutions for the SARS CoV-2 coronavirus.

●

~~March 16, 2020 - SteraMist~~® ~~Deployed to Fight SARS-CoV-2 coronavirus in United States~~

●

~~March 16, 2020 – SteraMist~~® ~~qualified to meet the~~ ~~EPA Emerging Viral Pathogen Guidance for Antimicrobial Pesticides~~ ~~with the SteraMist~~®~~Environment System for room fogging/misting against SARS-CoV-2 coronavirus, the novel coronavirus that causes COVID-19 and was added to the EPA N List against SARS-CoV-2.~~

●

~~March 25, 2020 - SteraMist~~® ~~utilized in Singapore to help reopen mosques~~

●

~~In March 2020, convertible notes with a principal balance of $4,500,000 were converted~~ ~~into 8,333,332 shares of our common stock~~ ~~at a conversion price of $0.54 per share and the remaining outstanding balance of $500,000 was repaid in the form of cash.~~

During the first quarter of ~~2020,~~2021, we ~~experienced the following:~~

●

~~Sold substantially all~~hired one Vice President of ~~our equipment inventory,~~Sales, each of whom, along with a ~~backlog and demand for 91 additional units,~~

●

~~Most New equipment orders require~~Vice President of Sales, hired in the fourth quarter of 2020, attended a ~~50% deposit, with balance due on most orders prior~~week-long sales seminar hosted by TOMI at the end of February 2021. The sales seminar was intended to ~~final shipment of products.~~

●

~~Increased demand on solution re-orders as disinfecting and~~educate each sales professional about disinfection decontamination ~~procedures have increased exponentially across the world,~~

●

~~Service revenue grew exponentially as the outbreak spread and demand for disinfecting and decontamination services increased,~~

●

~~Exclusivity~~competition in ~~TSN was revoked as demand surged and new providers requested equipment, solution and training to provide disinfecting and decontamination services,~~

●

New channels were opened as decontamination and disinfecting processes are updated and implemented, including but not limited to, fire departments, morgues, FAA, police departments, county and state health departments, cruise ships, infectious disease research facilities, military and ambulances,

●

C~~onvertible notes~~ ~~with a principal balance of $4,500,000 were converted~~ ~~into 8,333,332 shares of our common stock~~ ~~at a conversion price of $0.54 per share~~,their respective divisions and the ~~remaining outstanding balance~~advantages of ~~$500,000 was repaid.~~

●

~~Staffing – increased demand has led to the hiring~~SteraMist technology and ~~onboarding of additional employees to assist in a wide variety of company operations, from accounting, procurement, customer satisfaction to quality control.~~

~~Subsequent Events:~~

~~Following are the significant events during the second quarter 2020:~~

●

~~April 23, 2020 – Study results showcasing SteraMist~~® ~~efficacy on the disinfection and reuse of N95 masks published.~~

●

~~April 27, 2020 – SteraMist~~® ~~Deployed to Meet Urgent Need for Decontamination and Reuse of N95 Masks for Healthcare Workforce~~

●

~~April 28, 2020 – SteraMist~~® ~~Disinfection Used to Combat Coronavirus Throughout the United States with Expansion of its Service Network~~

●

~~April 29, 2020 – SteraMist~~® ~~Demand for SteraMist BIT Solution Surges~~

●

TOMI continues to see increased domestic and international demand for its products over the foreseeable future. TOMI has expanded its markets into the private aviation sector in Germany, multiple market segments in Indonesia and hospital-healthcare, military and homeland security in Singapore.

products.

On January 15, 2021, Dr. Halden Shane presented at the Needham Virtual Growth Conference while continuing to pursue and enhance SteraMist media presence across many platforms. Dr. Shane will be returning on May 18, 2021 (12:45pm – 1:25pm Eastern) as he presents at the 16thannual Needham virtual technology and media conference.

As conferences and tradeshows are reopening in the second half of 2021 for companies to exhibit live, TOMI will be attending multiple shows across the country with our new Vice Presidents of Sales in attendance. It is critical for TOMI to perform live demonstrations to showcase the difference between our SteraMist iHP technology and our competitors. TOMI looks forward to making a large impact with live demonstrations of SteraMist disinfection technology throughout our multiple divisions.

Research ~~Studies~~Studies:

Due to the pandemic, there have been significant delays by U.S. regulatory agencies in approving new submissions, including TOMI's new 1% registration focusing on direct food and agricultural applications. The 1% label has been delayed by EPA due to the reallocation of staff resources responding to an influx of product submissions to deal with COVID-19 (TOMI successfully added Emerging Pathogen claims and was added to EPA list in March 2020.), significantly delaying all other PRIA actions, well documented delays caused by staffing vacancies, and the continuing prohibition of in person meetings.

We continue to work with our German aircraft partner and Boeing in a third-party test required for the aviation industry. We will incur no costs for this work as both testing partners are clients. We anticipate the testing will be completed in the second quarter of 2021.

TOMI has engaged HYGCEN Germany GmbH to perform a quantitative test of germ carriers for airborne room disinfection and testing of the effectiveness of a method for disinfecting room air to meet the new EU norm (standard) EN 17272. Certification that Binary Ionization Technology meets the new standard will continue to position iHP as the premier decontamination/disinfection technology available on the market today.

We continue to work with the Virginia State University Agricultural Research Station and its partner, Arkema on a food safety pilot study based on novel, nonthermal, and environmentally friendly technology to control foodborne pathogens on industrial hemp seed and strawberry as representative model foods. The study will investigate the efficacy of aerosolized hydrogen peroxide in inactivating foodborne pathogens – determining the optimum treatment conditions on microbial and physical quality of the two model products. We anticipate the pilot to be completed by the second quarter of 2021.

We are currently working with University of Virginia on two separate studies. First, we are working on a study on SteraMist’s efficacy against SARS-CoV-2, and we have observed preliminary successful results and are waiting for the final published paper. Second, we are working on a study against Adenovirus using the handheld SteraMist Surface Unit and testing spray and contact time variables, and we are waiting for the results. We anticipate the testing will be completed by the third quarter of 2021.

TOMI has partnered with the Department of Chemistry and Biochemistry of Texas Tech University to conduct a wide range of studies on spray pattern, deposition, and hydrogen peroxide content in order to compare our 1% label to other similar products on the market.

TOMI's long term relationship with USDA Agricultural Research Service continues to achieve results. In March 2021, an article entitled "Hydrogen peroxide residue on tomato, apple, cantaloupe, and Romaine lettuce after treatments with cold plasma-activated hydrogen peroxide” was accepted for publication in the Journal of Food Microbiology. TOMI has also begun discussions with another ARS facility to evaluate the benefits of iHP on blueberries to prevent rot and reduce post-harvest losses.

~~We continue to participate~~As previously reported for a couple years, we have participated in a large multi-year federal funded study, known as the “SHIELD study”, that compares hospital manual cleans to a SteraMist®mechanical clean. Preliminary results collected by the current hospitals in the study is showing a decrease in the ~~transference~~transfernce of pathogens resulting in HAIs and C.Clostridium difficile infections in the rooms that used SteraMist® for their terminal ~~clean,~~clen, as compared to the rooms that have been manually cleaned. ~~The University of Michigan, a recognized teaching university hospital, joined~~We are eager to report that enough data has been collected to complete the ~~California hospitals~~study in ~~this Shield Study in the second quarter 2020, allowing for additional collection of~~2021, and we expect that data to ~~validate~~be provided to the ~~value of SteraMist~~®examiners with a published paper to soon follow. ~~technology in hospitals.~~

~~Product Development~~

~~We have added four new products to our growing line of products:~~

●

The SteraMist Surface Unit has been upgraded to a new model, the HHA-103. This model keeps the same functionality of the previous model with the featured addition of a new Harting™ Camlock port to the unit. This upgraded port allows for a more secure connection between the applicator and the Surface Unit, effectively latching the connection in place and eliminating the presence of any possible pulling or tilting that could compromise the connection integrity over time. Additionally, the unit features additional room within the unit for applicator and accessory storage.

●

~~A single applicator build-in unit for decontamination chambers and cage washers, which was recently successfully validated at the University of Houston.~~

●

~~A decontamination cart for a Pfizer facility. We will be designing and engineering a second SteraMist~~® ~~mobile decontamination cart for this same facility by the second quarter of 2020.~~

●

A stainless-steel mobile 90-degree applicator and the answer to the mobile treatment and decontamination of BSC cabinets and isolators. The 90-degree applicator product has led to a partnership with a large design and manufacturing company of washing and contamination control systems, and we plan on installing an all-in-one disinfection solution to Gnotobiotic Housings with our partner.

~~During 2020, we will continue our focus on improving our SteraMist~~® ~~Environment System and the development of a proprietary software that will be integrated into the next generation of SteraMist~~® equipment, both mobile and permanent. The new software will improve communication between our equipment and the end user’s system, provide improved reporting results and simplify the overall usage of the system itself. We are in the final testing and validation phase of the new Environment System prototype, expecting to begin commercialization in 2020.

We are in the design phase with our partner Arkema and their client (a global food storage and safety company) on an engineered concept for the decontamination of large industrial food warehouse facilities. The concept is a six (6) applicator fully automated fogging system permanently mounted on a hydraulic lift that is capable of coverage in high-volume spaces. We are in early phases of the project and don’t have an expected commercialization date.

Registrations & Intellectual Property (IP):

Our portfolio includes more than twenty (20) Utility Patent applications worldwide for both method and system claims on SteraMist® BIT™, either published or undergoing prosecution. Most recently, in November 2020, we were granted utility patents in Australia and Israel for our SteraMist® BIT™ technology. In ~~February~~the recent past, we have obtained two related US utility patents giving us protection of our technology until the year 2038, and we are pursuing further claims to additional capabilities in on-going US and worldwide patent applications. In May 2020, ~~SteraMist equipment and BIT solution was registered with the Chinese Center~~we filed a PCT application for Disease Control and Prevention (China CDC). After a three (3) year-long submission process, we recently received confirmation that two (2) separate registrations - SteraMist equipment registration and BIT solution registration - have now been officially approved and registered with the China CDC. SteraMist is now the industry standard for disinfection throughout all of China. This registration allows China to take advantagefurther additional applications of SteraMist ~~disinfection~~® BIT™ which were determined to be novel and ~~decontamination in a variety of verticals such as healthcare, pharmaceutical, commercial and residential, schools, and throughout~~inventive by the ~~community.~~international search authority.

Further in 2020, we submitted utility patents in multiple countries which are all in the national stage for review under the patent prosecution highway for claims found novel and inventive by the international search authority. Once these are received, we will hold international acceptance for the inherited patents and our newly received patents. During 2020, we were awarded a design patent on our surface-mounted applicator device in the United States, China, Japan, Taiwan, and Korea. We have filed and have been granted or have pending acceptance on thirty-two (32) separate design patents for our: Decontamination Chamber(s), Decontamination Applicator, Decontamination Cart, Applicator, and Surface Mounted Applicator 90-Degree Device. These patents are published around the world, including but not limited to United States, China, Hong Kong, Europe, United Kingdom, Singapore, Taiwan, Vietnam, Canada, South Korea, and Japan.

InOur products are sold around the world under various brand names and trademarks. We consider our brand names and trademarks to be valuable in the marketing of our products. As of March ~~2020, our Binary Ionization Technology® (BIT™) Solution qualified to meet~~1, 2021, we held a total of one hundred seventy-eight (178) trademarks (word and logo) registered or pending across the ~~EPA Emerging Viral Pathogen Guidance~~globe. TOMI registers marks in seven (7) classes of specification of goods and services: Class 1 for ~~Antimicrobial Pesticides with the SteraMist Environment System~~Chemicals for ~~room fogging/misting against SARS-CoV-2, the novel coronavirus that causes COVID-19. The EPA Emerging Viral Pathogen Guidance~~Treating Hazardous Waste, Class 5 for ~~Antimicrobial Pesticides is important because the occurrence of emerging viral pathogens is less common~~Disinfectants, All-Purpose for Hard Surfaces and ~~predictable than established pathogens~~for Treating Mold, Class 7 for Handheld Power Operated Spraying Machines, Class 11 for Sterilizers for Medical Use and there are currently no other EPA-registered disinfectant product labels with claims against COVID-19. The SARS-CoV-2, the novel coronavirus that causes COVID-19 qualifies as an emerging viral pathogen. Our Binary Ionization Technology (BIT) Solution, used exclusively in tandem with SteraMist equipment including the Surface UnitAir Purification, Class 35 for Business Consultation and ~~Environment System, is currently listed on List G~~Management Services, Class 37 for ~~Norovirus, List H~~General Disinfecting Services, and Class 40 for ~~MRSA, List K for Clostridium difficile spores, List L for Ebola, List M for H1N1,~~Chemical Decontamination and now List N: Disinfectants for Use Against SARS-CoV-2. With labeled efficacy for large and small enveloped viruses in addition to other pathogens, we have confidence this EPA addition will support client efforts to reduce the ongoing spread of the COVID-19.Manufacturing Services.

Financial Operations Overview

Our financial position as of March 31, ~~2020~~2021 and December 31, ~~2019~~2020, respectively, was as follows:

			March 31, 2021	December 31, 2020
	March 31, 2020 (Unaudited)	December 31, 2019	Unaudited
Total shareholders’ equity	$8,324,000	$890,000	$11,920,000	$13,203,000
Cash and cash equivalents	$3,756,000	$897,000	$3,946,000	$5,199,000
Accounts receivable, net	$3,146,000	$1,495,000	$3,743,000	$3,717,000
Inventories, net	$636,000	$2,315,000
Inventories			$4,765,000	$3,782,000
Prepaid expenses	$171,000	$188,000	$316,000	$421,000
Vendor Deposits	$1,267,000	$141,000	$146,000	$389,000
Current liabilities (excluding convertible notes)	$2,610,000	$1,302,000
Convertible notes payable, net	$-	$5,000,000
Other Receivables			$-	$199,000
Current liabilities			$2,789,000	$2,203,000
Long-term liabilities	$1,015,000	$1,034,000	$1,342,000	$1,364,000
Working Capital (excluding convertible notes)	$6,365,000	$3,734,000
Working Capital (including convertible notes)	$6,365,000	$(1,266,000)
Working Capital			$10,128,000	$11,503,000

During the ~~three months~~quarter ended March 31, ~~2020,~~2021, our debt and liquidity positions were affected by the following:

●

Net cash ~~provided from~~used in operations of ~~approximately $3,316,000~~$1,225,000.

●

~~Vendor deposits of approximately $1,267,000~~

●

~~Customer deposits of approximately $1,018,000~~

●

~~Conversion of convertible notes payable with a principal balance of $4,500,000 into shares of common stock~~

●

~~Repayment of convertible note payable with a principal balance of $500,000~~

Results of Operations for the ~~Three Months~~Quarter Ended March 31, ~~2020~~2021 Compared to the ~~Three Months~~Quarter Ended March 31, ~~2019~~2020

	Three Months Ended
	March 31, 2020 (Unaudited)	March 31, 2019 (Unaudited)	For the three months ended March 31,		Change
			2021	2020	$	%
Revenue, Net	$7,053,000	$1,253,000	$2,073,000	$7,053,000	$(4,980,000)	-71%
Gross Profit	$4,488,000	$759,000	1,235,000	4,488,000	(3,253,000)	-72%
Total Operating Expenses (1)	$1,829,000	$1,627,000	2,745,000	1,829,000	916,000	50%
Income (Loss) from Operations	$2,659,000	$(868,000)	(1,510,000)	2,659,000	(4,169,000)	NM
Total Other Income (Expense)	$(40,000)	$(67,000)	(1,000)	(40,000)	39,000	-98%
Net Income (Loss)	$2,619,000	$(935,000)	$(1,511,000)	$2,619,000	$(4,130,000)	NM
Basic Net Income (Loss) per share	$0.02	$(0.01)	$(0.09)	$0.17	$(0.26)	NM
Diluted Net Income (Loss) per share	$0.02	$(0.01)	$(0.09)	$0.14	$(0.23)	NM

(1)

Includes ~~approximately~~$0 and $183,000 ~~and $81,000~~ in non-cash equity compensation expense for the three months ended March 31, ~~2020~~2021 and ~~2019,~~2020, respectively.

(2)

NM – Not Meaningful

~~Net Revenue~~

Sales

~~Total~~During the three months ended March 31, 2021 and 2020, we had net revenue of approximately $2,073,000 and $7,053,000, respectively, representing a decrease in revenue of approximately $4,980,000 or 71%.

We experienced a decline in our revenue for the three months ended March 31, ~~2020 and 2019, was approximately $7,053,000 and $1,253,000, respectively, representing an increase of $5,800,000, or 463%~~2021 as compared to the same quarter in the prior year ~~period.~~primarily due to the significant increase of demand caused by the onset of COVID-19 pandemic in March of 2020. We were positioned well to respond to the pandemic related spike in demand due to our inventory levels and increased production capacity, which led to substantial revenue growth in the first and second quarter of 2020. However, during second half of 2020 and early 2021, many of our established vertical clients were closed or required to reduce operation due to the impact of COVID-19 pandemic on their businesses. The ~~increase in revenue was attributable to increased global demand for disinfection~~markets that were negatively affected included our life sciences clients that were nonessential, University and ~~infectious disease control products~~privately owned vivarium labs, and many nonessential pharmaceutical research companies globally. In addition, the healthcare industry has shifted virtually all of its focus and resources in response to the ~~SARS CoV-2 coronavirus~~ ~~global pandemic. In the first quarter we saw significant demand~~pandemic and therefore substantially reduced elective surgical and clinical related services, resulting in limited non-essential onsite personnel. These trends made it more difficult for us to demo our ~~product with~~equipment and execute our ~~Hospital-Healthcare~~sales and ~~TSN sales as a result of the~~ ~~SARS CoV-2 coronavirus~~ global pandemic. We expect the revenue to continue to grow as our customers update their requirements, processes and procedures to include decontamination and disinfecting services into their regular routines.marketing strategies.

~~In the first quarter, we saw a rapid expansion of our customer list and continued to see strong reorders for solution from our existing customers. Our new customer pipeline remains strong.~~ As customers mature through the product and adoption cycle and our sales pipeline converts to revenue, we expect to ~~have~~generate more predictable sales quarter over quarter. Further, as the COVID-19 pandemic subsides, we expect that the demand for our products and services will continue as we are building a team to address the post COVID-19 pandemic market opportunities.

Net Revenue

Product and Service Revenue

	For the three months ended March 31, (Unaudited)		For the three months ended March 31,		Change
	2020	2019	2021	2020	$	%
SteraMist Product	$6,638,000	$1,029,000	$1,661,000	$6,638,000	$(4,977,000)	(75)%
Service and Training	415,000	224,000	412,000	415,000	(3,000)	(1)%
Total	$7,053,000	$1,253,000	$2,073,000	$7,053,000	$(4,980,000)	(71)%

Revenue by Geographic Region

	For the three months ended March 31, (Unaudited)		For the three months ended March 31,		Change
	2020	2019	2021	2020	$	%
United States	$3,569,000	$1,136,000	$1,804,000	$3,569,000	$(1,765,000)	(49)%
International	3,484,000	117,000	269,000	3,484,000	(3,215,000)	(92)%
Total	$7,053,000	$1,253,000	$2,073,000	$7,053,000	$(4,980,000)	(71)%

Cost of Sales

	For the three months ended March 31,		Change
	2021	2020	$	%
Cost of Sales	$838,000	$2,565,000	$(1,727,000)	(67)%

Cost of sales was ~~approximately~~$838,000 and $2,565,000 ~~and $493,000~~ for the three months ended March 31, 2021 and 2020, ~~and 2019,~~ respectively, ~~an increase~~a decrease of ~~$2,072,000, in~~$1,727,000, or 67%, compared to the ~~current year period.~~ prior year. The primary reason for the ~~increase~~decline in cost of sales is attributable to ~~the increase in~~lower revenue in the current ~~year~~.quarter. Our gross profit as a percentage of sales for the three months ended March 31, ~~2020~~2021 was ~~63.6%~~59.6% compared to ~~60.6%~~63.6% in the same prior ~~period.~~period, respectively. The ~~higher~~lower gross profit is attributable to the product mix in sales. As revenues continue to grow and we are able to negotiate more favorable pricing from our vendors, we anticipate that our cost per unit could decrease.

Professional Fees

	For the three months ended March 31,		Change
	2021	2020	$	%
Professional Fees	$173,000	$136,000	$37,000	27%

~~Professional fees were approximately $136,000 and $105,000 for the three months ended March 31, 2020 and 2019, respectively, an increase of approximately $31,000, or 29%, in the current year period.~~

Professional fees are comprised mainly of legal, accounting, and financial consulting fees.

Professional fees were $173,000 and $136,000 for the three months ended March 31, 2021 and 2020, respectively, an increase of approximately $37,000, or 27%, in the current year period. The increase is attributable to additional professional fees in connection with the maintenance of our intellectual property.

Depreciation and Amortization

	For the three months ended March 31,		Change
	2021	2020	$	%
Depreciation and Amortization	$83,000	$172,000	$(89,000)	(51)%

Depreciation and amortization were approximately ~~$172,000~~$83,000 and ~~$177,000~~$172,000 for the three months ended March 31, 2021 and 2020, ~~and 2019,~~ respectively, representing a decrease of ~~$5,000,~~$89,000, or ~~3%,~~51%. The decline is due to intangible assets that became fully amortized in 2020 which has led to a lower amortization expense in the current year period.

Selling Expenses

	For the three months ended March 31,		Change
	2021	2020	$	%
Selling Expenses	$474,000	$379,000	$95,000	25%

Selling expenses ~~were approximately $379,000 and $442,000~~ for the three months ended March 31, 2021 were approximately $474,000, as compared to $379,000 for the quarter ended March 31, 2020, representing an increase of approximately $95,000 or 25%.

The increase in selling expense is attributable to a higher employee headcount and ~~2019, respectively, a decrease of $63,000, or 14%,~~the related increase in ~~the current year period.~~payroll. We continue to invest and allocate resources into our sales, marketing and advertising initiatives and have increased efforts in the current year in order to further develop our brand recognition and grow our base of customers. The decline in selling expenses is primarily due to a lower employee headcount in our sales department as well as lower tradeshow costs in the current year period. We expect tradeshow expenses to continue to decline this year in the post CoV-2 world, as physical distancing continues to remain in effect. We expect to increase our sales team during 2020 to address the increase in the demand for our products and services.

Research and Development

	For the three months ended March 31,		Change
	2021	2020	$	%
Research and Development	$196,000	$59,000	$137,000	232%

Research and development expenses ~~were approximately $59,000 and $93,000~~ for the three months ended March 31, ~~2020 and 2019, respectively, a decrease of $34,000, or 36%, in the current year period. The primary reason~~2021 were approximately $196,000, as compared to $59,000 for the ~~decrease~~quarter ended March 31, 2020, representing an increase of approximately $137,000, or 232%. The increase in research and development expenses is attributable to ~~the timing of costs related to testing~~new product development and ~~studies that occurred in the same prior period.~~increased testing.

Equity Compensation Expense

	For the three months ended March 31,		Change
	2021	2020	$	%
Equity Compensation Expense	$-	$183,000	$(183,000)	(100)%

Equity compensation expense was ~~approximately $183,000and $81,000~~$0 and $183,000 for the three months ended March 31, ~~2020~~2021 and ~~2019,~~2020, respectively, representing ~~an increase~~a decrease of ~~$102,000 or 136%.~~$183,000. The decrease in equity compensation expense relates to the timing of warrants and options issued to executives and consultants in 2020.

Consulting Fees

	For the three months ended March 31,		Change
	2021	2020	$	%
Consulting Fees	$106,000	$82,000	$24,000	29%

Consulting fees were ~~approximately~~$106,000 and $82,000 ~~and $35,000~~ for the three months ended March 31, ~~2020~~2021 and ~~2019,~~2020, respectively, representing an increase of ~~$47,000,~~$24,000, or ~~133%~~29%, in the current ~~year~~quarter period. The increase is due to the timing of certain projects that occurred in the ~~first quarter of 2020~~current year that did not occur in the same prior year period.

General and Administrative Expense

General and administrative expense was approximately $818,000 and $695,000 for the three months ended March 31, 2020 and 2019, respectively, an increase of $123,000, or 18%, in the current year period. The increase in General and administrative expense is attributable to a higher employee headcount and higher wages as well as an increase in international product registration.

	For the three months ended March 31,		Change
	2021	2020	$	%
General and Administrative	$1,712,000	$818,000	$894,000	109%

General and administrative expense includes salaries and payroll taxes, rent, insurance expense, utilities, office expense and product registration costs.

~~Other Income~~General and ~~Expense~~

~~Amortization of debt discount~~administrative expense was ~~approximately $0~~$1,712,000 and ~~$17,534~~$818,000 for the three months ended March 31, 2021 and 2020, respectively, an increase of $894,000, or 109%, in the current quarter period. The increase in General and ~~2019, respectively. Amortization of debt discount for the three months ended March 31, 2020~~administrative expense is attributable to a higher employee headcount and ~~2019, consists of the amortization of debt discount on the $6,000,000 principal amount of Notes issued in March~~higher wages.

Other Income and ~~May 2017. The debt discount was amortized over the life of the Notes utilizing the effective interest method.~~Expense

	For the three months ended March 31,		Change
	2021	2020	$	%

Interest Income	-	1,000	(1,000)	NM
Interest Expense	(1,000)	(41,000)	40,000	(98)%
Other Income (Expense)	$(1,000)	$(40,000)	$39,000	(98)%

Interest income was approximately ~~$500~~$0 and $1,000 for the three months ended March 31, ~~2020~~2021 and ~~2019,~~2020, respectively.

Interest expense was ~~approximately~~$1,000 and $41,000 ~~and $50,000~~ for the three months ended March 31, 2021 and 2020, ~~and 2019,~~ respectively. Interest expense for the three months ended March 31, 2020 and 2019 consisted of the interest incurred on the $6,000,000 principal amount of Notes issued in March and May 2017 of which $4,500,000 was converted to common stock in March, 2020 and the remaining $500,000 was paid in cash in March 2020.

~~Net Income (Loss)~~

Net income was approximately $2,619,000 compared to a net loss of approximately ($935,000) for the three months ended March 31, 2020 and 2019, respectively, an increase in net income of $3,554,000, or 380%, in the current year period. The primary reasons for the higher net income is attributable to:

●

~~Higher sales and gross profit of approximately $5,800,000 and $3,729,000, respectively;~~

●

~~Lower other expenses of approximately $27,000, offset by~~

●

~~Higher operating expenses of approximately $202,000;~~

Liquidity and Capital Resources

As of March 31, ~~2020,~~2021, we had cash and cash equivalents of ~~approximately $3,756,000~~$3,946,000 and working capital of ~~$6,365,000.~~$10,128,000. Our principal capital requirements are to fund operations, invest in research and development and capital equipment, and the continued costs of public company filing requirements. We have historically funded our operations through funds generated through operations and debt and equity financings.

For the three months ended March 31, 2021, we incurred a loss from operations of ($1,510, 000) and for the three months ended March 31, 2020, we generated income from operations of ~~approximately $2,659,000 and for the three months ended March 31, 2019 we incurred losses from operations of approximately ($868,000). The cash provided from~~$2,659,000. Cash used in operations for the three months ended March 31, ~~2020,~~2021, was ~~approximately $3,316,000. The cash used in~~($1,225,000). Cash provided from operations was ~~approximately ($649,000)~~$3,316,000 for the three months ended March 31, ~~2019.~~

During the first quarter of 2020, due to the SARS CoV-2 uncertainty and to mitigate our credit risk, we modified our customer payment terms requiring a 50%-100% deposit on most equipment orders which improved our cash flows and liquidity. We had customer deposits of approximately $1,017,000 as of March 31, 2020.

As of March 31, 2020, in response to our inventory order quantities and request for expediting our products, our vendors required us to place deposits of approximately $1,267,000 on future inventory orders.

A breakdown of our statement of cash flows for the three months ended March 31, ~~2020~~2021 and ~~2019~~2020 is provided below:

	For the three months ended March 31,
	2021	2020
Net Cash Provided By (Used) in Operating Activities	$(1,225,000)	$3,316,000
Net Cash Used in Investing Activities	$(28,000)	$(15,000)
Net Cash (Used) in Financing Activities:	$-	$(443,000)

Operating Activities

Cash used in operating activities for the three months ended March 31, 2021 was ($1,225,000), compared to cash provided by ~~operating activities~~operations for the three months ended March 31, 2020 ~~was approximately $3,316,000, compared to cash used in operations for the three months ended March 31, 2019~~ of ~~approximately ($649,000).~~$3,316,000. Our cash provided by operations ~~improved~~declined in the current year period as a result of ~~increased~~lower revenue and a net ~~income and customer deposits placed on future orders offset by increased accounts receivable and vendors deposits.~~loss.

Investing Activities

Cash used in investing activities for the three months ended March 31, 2021 and 2020 was $28,000 and ~~2019 was approximately~~ $15,000, ~~and $160,000,~~ respectively. ~~Cash used in investing activities decreased approximately $145,000 primarily due to software development costs and the acquisition of fixed assets in the prior year period.~~

Financing Activities

Cash used inby financing activities for the three months ended March 31, 2021 and 2020 was $0 and ~~2019 were approximately~~ $443,000 ~~and $0,~~ respectively. The cash used in financing activities ~~increased~~ in the ~~current~~prior year period was due to the repayment of the principal balance of the convertible note of $500,000 offset by proceeds from the exercise of warrants in the amount of ~~$57,500.~~$58,000.

Liquidity

Our revenues can fluctuate due to the following factors, among others:

●

~~Ramp~~ramp up and expansion of our internal sales force and manufacturers’ representatives;

●

~~Length~~length of our sales cycle;

●

~~Global~~global response to the ~~outbreak of SARS CoV-2;~~COVID-19 pandemic and market demand for our products;

●

~~Expansion~~expansion into new territories and markets; and

●

~~Timing~~timing of orders from distributors.

We could incur operating losses and an increase of costs related to the continuation of product and technology development, and sales expense as we continue to grow our sales teams and geographic presence, tooling capital expenditures as we ramp up and streamline our production and administrative activities including compliance with ~~Sox~~the Sarbanes-Oxley Act of 2002 Section 404.

Management has taken and will endeavor to continue to take a number of actions in order to improve our results of operations and the related cash flows generated from operations in order to strengthen our financial position, including the following items:

●

~~Expanding~~expanding our label with the EPA to further our product registration internationally;

●

~~Continued~~continued expansion of our internal sales force and manufacturer representatives in an effort to drive global revenue in all verticals;

●

~~Source~~Continue research and development and add new products to our “Stera” product line

●

source alternative lower-cost suppliers;

●

~~Expansion~~expansion of international distributors; and

●

~~Continued~~continued growth in all of our verticals.

We expect that the cash we generate from our core operations will generally be sufficient to cover our future capital expenditures and to pay down our near-term debt obligations, although we may choose to seek alternative financing sources.

We believe that our existing balance of cash and cash equivalents and amounts expected to be provided by operations will provide us with sufficient financial resources to meet our cash requirements for operations, working capital and capital expenditures over the next twelve months.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations is based upon our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The estimation process requires assumptions to be made about future events and conditions, and as such, is inherently subjective and uncertain. Actual results could differ materially from our estimates.

The SEC defines critical accounting policies as those that are, in management’s view, most important to the portrayal of our financial condition and results of operations and most demanding of our judgment. We consider the following policies to be critical to an understanding of our condensed consolidated financial statements and the uncertainties associated with the complex judgments made by us that could impact our results of operations, financial position and cash flows.

Revenue Recognition

~~The Company~~

We must use judgment to determine: a) the number of performance obligations based on the determination under step (ii) above and whether those performance obligations are distinct from other performance obligations in the contract; b) the transaction price under step (iii) above; and c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above.

~~Disaggregation of Revenue~~

~~The following table presents our revenues disaggregated by revenue source.~~

~~Product and Service Revenue~~

For the three months ended March 31,
(Unaudited)

2020

2019

SteraMist Product
$6,638,000
$1,029,000
Service and Training
415,000
224,000
Total
$7,053,000
$1,253,000

~~Revenue by Geographic Region~~

For the three months ended March 31,
(Unaudited)

2020

2019

United States
$3,569,000
$1,136,000
International
3,484,000
117,000
Total
$7,053,000
$1,253,000

Costs to Obtain a Contract with a Customer

Contract Balances

As of March 31, ~~2020,~~2021, and December 31, ~~2019~~2020 we did not have any unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.

Arrangements with Multiple Performance Obligations

~~Significant~~Significant Judgments

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the accompanying condensed consolidated financial statements and the accompanying notes. Actual results could differ materially from these estimates. On an ongoing basis, we evaluate our estimates, including those related to accounts receivable, inventory, fair values of financial instruments, intangible assets, useful lives of intangible assets and property and equipment, fair values of stock-based awards, income taxes, and contingent liabilities, among others. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of our assets and liabilities.

Fair Value Measurements

~~Level 1:~~

Level 1:	Quoted prices in active markets for identical assets or liabilities. ~~Level 2:~~ Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data or substantially the full term of the assets or liabilities. ~~Level 3:~~ ~~Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities.~~
Level 2:	Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3:	Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities.

Our financial instruments include cash and cash equivalents, accounts receivable, accounts payable and accrued expenses. All these items were determined to be Level 1 fair value measurements.

The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximated fair value because of the short maturity of these instruments.

Cash and Cash Equivalents

Accounts Receivable

Our accounts receivable are typically from credit worthy customers or, for certain international customers, are supported by pre-payments. For those customers to whom we extend credit, we perform periodic evaluations of them and maintain allowances for potential credit losses as deemed necessary. We have a policy of reserving for doubtful accounts based on our best estimate of the amount of potential credit losses in existing accounts receivable. We periodically review our accounts receivable to determine whether an allowance is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt. Account balances deemed to be uncollectible are charged to the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.

Inventories

Inventories are valued at the lower of cost or market using the first-in, first-out (FIFO) method. Inventories consist primarily of finished ~~goods~~.goods.

We expense costs to maintain certification to cost of goods sold as incurred.

Property and Equipment

Leases

In February 2016, the FASB issued ASU No. 2016-02 ~~(“ASC 842”)~~(ASC 842), Leases, to require lessees to recognize all leases, with certain exceptions, on the balance sheet, while recognition on the statement of operations will remain similar to current lease accounting. Subsequently, the FASB issued ASU No. 2018-10, Codification Improvements to Topic 842, Leases, ASU No. 2018-11, Targeted Improvements, ASU No. 2018-20, Narrow-Scope Improvements for Lessors, and ASU 2019-01, Codification Improvements, to clarify and amend the guidance in ASU No. 2016-02. ASC 842 eliminates real estate-specific provisions and modifies certain aspects of lessor accounting. This standard is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted. We adopted ASC 842 as of January 1, 2019 using the modified retrospective basis with a cumulative effect adjustment as of that date. In addition, we elected the package of practical expedients permitted under the transition guidance within the new standard, which allowed us to carry forward the historical determination of contracts as leases, lease classification and not reassess initial direct costs for historical lease arrangements. Accordingly, previously reported financial statements, including footnote disclosures, have not been recast to reflect the application of the new standard to all comparative periods presented.

We have elected not to present short-term leases on the ~~condensed~~ consolidated balance sheet as these leases have a lease term of 12 months or less at lease inception and do not contain purchase options or renewal terms that we are reasonably certain to exercise. All other lease assets and lease liabilities are recognized based on the present value of lease payments over the lease term at commencement date. Because most of our leases do not provide an implicit rate of return, we used our incremental borrowing rate based on the information available at adoption date in determining the present value of lease payments.

Capitalized Software Development Costs

In accordance with ASC 985-20 regarding the development of software to be sold, leased, or marketed ~~the Company expenses~~we expense such costs as they are incurred until technological feasibility has been established, at and after which time those costs are capitalized until the product is available for general release to customers. The periodic expense for the amortization of capitalized software development costs will be included in cost of sales.

Accrued Warranties

Accrued warranties represent the estimated costs, if any, that will be incurred during the warranty period of our products. We estimate the expected costs to be incurred during the warranty period and record the expense to the ~~condensed~~ consolidated statement of operations at the date of sale. Our ~~manufacturer assumes~~manufacturers assume the warranty against product defects ~~for one year from date of sale,~~ which we extend to our customers upon sale of the product. We assume responsibility for product reliability and results.

Income Taxes

Net Income (Loss) Per Share

Equity Compensation Expense

On July 7, 2017, our shareholders approved the 2016 Equity Incentive Plan, ~~(the “2016 Plan”).~~or the 2016 Plan. The 2016 Plan authorizes the grant of stock options, stock appreciation rights, restricted stock, restricted stock units and performance units/shares. Up to ~~5,000,000~~625,000 shares of common stock are authorized for issuance under the 2016 Plan. Shares issued under the 2016 Plan may be either authorized but unissued shares, treasury shares, or any combination thereof. Provisions in the 2016 Plan permit the reuse or reissuance by the 2016 Plan of shares of common stock for numerous reasons, including, but not limited to, shares of common stock underlying canceled, expired, or forfeited awards of stock-based compensation and stock appreciation rights paid out in the form of cash. Equity compensation expense will typically be awarded in consideration for the future performance of services to us. All recipients of awards under the 2016 Plan are required to enter into award agreements with ~~the Company~~us at the time of the award; awards under the 2016 Plan are expressly conditioned upon such agreements.

On December 30, 2020, we received shareholder approval to restate and amend the 2016 Equity Incentive Plan to increase the maximum number of shares of common stock authorized from issuance by 1,375,000, from 625,000 shares to 2,000,000.

Concentrations of Credit Risk

Long-Lived Assets Including Acquired Intangible Assets

Recent Accounting Pronouncements

Recently Issued Accounting Pronouncements

See Note 2 to the Condensed Consolidated Financial Statements contained in Item 1 above.

Off-Balance Sheet Arrangements

We do not have any transactions, agreements or other contractual arrangements that constitute off-balance sheet arrangements.

I~~tem~~Item 3. ~~Quantitative~~Quantitative and Qualitative Disclosures About Market Risk.

We are a smaller reporting company as defined by Rule 405 under the Securities Act of 1933, as amended, and Rule 12b-2 under the Exchange Act and are not required to disclose the information required by this Item 3 pursuant to Item 305(e) of Regulation S-K.Not Applicable

I~~tem~~Item 4. ~~Controls~~Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Principal Executive Officer and Principal Financial Officer, conducted an evaluation of the effectiveness of our disclosure controls and procedures (as is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this quarterly report on Form 10-Q. Based on that evaluation, our Principal Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting identified in management’s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) under the Exchange Act during the period covered by this Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on Effectiveness of Controls and Procedures

In designing and evaluating the disclosure controls and procedures and internal control over financial reporting, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures and internal control over financial reporting must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

P~~ART~~PART II: OTHER INFORMATION

I~~tem~~Item 1. ~~Legal~~Legal Proceedings.

From time to time, we may be involved in litigation relating to claims arising out of our operations in the normal course of business. We currently are not a party to any legal proceedings, the adverse outcome of which, in management’s opinion, individually or in the aggregate, would have a material adverse effect on our results of operations, financial position or cash flows. Regardless of the outcome, any litigation could have an adverse impact on us due to defense and settlement costs, diversion of management resources and other factors.

I~~tem~~Item 1A. ~~Risk~~Risk Factors.

~~While, as a smaller reporting company, we are not required to provide~~You should carefully consider the information ~~required by this Item 1A, you should carefully review and consider~~described in the ~~risk factors contained in our other reports and periodic filings with the SEC, including without limitation the risk factors contained under the caption “Item 1A—Risk~~“Risk Factors” insection of our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2019. The~~2020, as filed with the SEC on March 30, 2021. Except as noted below, there have been no material changes to the risk factors ~~discussed~~we previously disclosed in ~~that~~our filings with the SEC, including the Form ~~10-K do not identify all risks that we face because our business~~10-K. Our operations could also be affected by additional factors that are not presently known to us or by factors that we currently consider ~~to be~~ immaterial to our ~~operations.~~business.

The COVID-19 pandemic has increased the global demand for disinfection products and services that help prevent the spread and transmission of COVID-19 virus. Similarly, we have experienced a substantial increase in demand for our products and services in 2020 due to the pandemic, causing us to generate significant revenues and making us profitable for the first time in 2020. However, there is no guarantee that such pace of demand for our products and services will continue or grow in 2021 or beyond. During the first quarter of 2021, we experienced a reduction of demand due to various factors, including the closure of our major customers’ business operations due to the pandemic, which resulted in the suspension of many of our ongoing long-term projects. It is difficult to predict how COVID-19 pandemic will affect our financial performance in the remainder of 2021, as the global economy gradually reopens, our customers adjust and change their operations, and we implement new marketing and sales strategies in response. While we believe that certain trends may positively affect our sales, including our ability to onboard and expand our marketing program and provide in-person demo and additional federal funding for some of our customers for disinfection expenditures, we cannot be sure that such trends will continue, or such strategies will be successful. Moreover, various other factors, including those beyond our control, may cause a reduction in demand for our products. In particular, our existing and potential new customers may decide to adopt new disinfection protocols in response to improving COVID-19 conditions or allocate more resources to other aspects of their business, or search for other competitive products to meet their needs, any of which may reduce demand for our products and adversely affect our financial performance.

I~~tem~~Item 2. ~~Unregistered~~Unregistered Sales of Equity Securities and Use of Proceeds.

None.

I~~tem~~Item 3. ~~Defaults~~Defaults Upon Senior Securities.

None.

I~~tem~~Item 4. ~~Mine~~Mine Safety Disclosures.

Not applicable.

I~~tem~~Item 5. ~~Other~~Other Information.

None.

I~~tem~~Item 6. ~~Exhibits.~~Exhibits.

The documents listed in the Exhibit Index of this Form 10-Q are incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

TOMI ENVIRONMENTAL SOLUTIONS, INC.

	TOMI ENVIRONMENTAL SOLUTIONS, INC.

Date: May ~~14, 2020~~ 17, 2021	By:	/s/ Halden S. Shane
		Halden S. Shane
		Chief Executive Officer
		(Principal Executive Officer)



Date: May 17, 2021	By:	/s/ Nick Jennings

~~Date:~~ ~~May 14, 2020~~	~~By:~~	~~/s/~~ Nick Jennings
		~~Nick Jennings~~ Chief Financial Officer
		~~Chief Financial Officer (Principal~~(Principal Financial Officer and Principal Accounting Officer)

EXHIBIT INDEX

Incorporated by Reference

Filed

Herewith

Exhibit Number

Exhibit Description

Form

File No.

Exhibit

Filing

Date

~~10.1~~4.1

~~PPP Note~~Form of Warrant to Purchase Common Stock

4.2

Form of Non-Qualified Stock Option Agreement

31.1

Certification of Halden S. Shane, Chief Executive Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2

Certification of Nick Jennings, Chief Financial Officer, pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

~~32.1~~32.1##

Certification of Halden S. Shane, Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

~~32.2~~32.2##

Certification of Nick Jennings, Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS

XBRL Instance Document.

101.SCH

XBRL Taxonomy Extension Schema Document.

101.CAL

XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF

XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB

XBRL Taxonomy Extension Labels Linkbase Document.

101.PRE

XBRL Taxonomy Extension Presentation Linkbase Document.

+ Indicates a management contract or compensatory plan.

# This certification is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, ~~(Exchange Act),~~or the Exchange Act, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, ~~as amended (Securities Act),~~ or the Exchange Act.


CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS		2 4

PART I	FINANCIAL INFORMATION

Item 1	Financial Statements.	3 5

Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations.	24 28

Item 3	Quantitative and Qualitative Disclosures About Market Risk.	37 45

Item 4	Controls and Procedures.	37 45

PART II	OTHER INFORMATION

Item 1	Legal Proceedings.	38 46

Item 1A	Risk Factors.	38 46

Item 2	Unregistered Sales of Equity Securities and Use of Proceeds.	38 46

Item 3	Defaults Upon Senior Securities.	38 46

Item 4	Mine Safety Disclosures.	38 46

Item 5	Other Information.	38 46

Item 6	Exhibits.	38 46

SIGNATURES		39 47

EXHIBIT INDEX		40 48

	Series A Preferred		Common Stock		Additional Paid in	Accumulated	Total Shareholders'
	Shares	Amount	Shares	Amount	Capital	Deficit	Equity
Balance at December 31, 2019	510,000	$5,100	124,700,418	$1,247,004	$43,136,683	$(43,499,243)	$889,543

Equity Compensation					209,961		209,961
Common Stock Issued for Services Provided			400,000	4,000	44,000		48,000
Conversion of Notes Payable into Common Stock			8,333,332	83,333	4,416,667		4,500,000
Warrants exercised			83,333	833	56,667		57,500
Net Income for the three months ended March 31, 2020						2,619,261	2,619,261
Balance at March 31, 2020	510,000	$5,100	133,517,083	$1,335,170	$47,863,978	$(40,879,982)	$8,324,265

	For the Three Months Ended March 31,
	2020	2019
Cash Flow From Operating Activities:
Net Income (Loss)	$2,619,261	$(934,532)
Adjustments to Reconcile Net Income (Loss) to		.
Net Cash Provided by (Used in) Operating Activities:
Depreciation and Amortization	171,909	176,845
Amortization of Lease Liability	39,329	39,644
Amortization of Debt Discount	-	17,534
Amortization of Software Costs	10,475	-
Equity Compensation Expense	182,772	80,917
Value of Equity Issued for Services	48,000	44,000
Reserve for Bad Debt	25,000	(105,000)
Inventory Reserve	(100,000)	-
Changes in Operating Assets and Liabilities:
Decrease (Increase) in:
Accounts Receivable	(1,676,539)	222,922
Inventory	1,815,942	288,827
Prepaid Expenses	16,807	6,792
Vendor Deposits	(1,125,508)	(79,275)
Other Assets	(8,924)	(64,914)
Increase (Decrease) in:
Accounts Payable	118,955	(475,851)
Accrued Expenses	232,813	225,072
Accrued Interest	(66,667)	(50,000)
Accrued Officer Compensation	30,383	(40,208)
Customer Deposits	1,017,533	(1,486)
Lease Liability	(35,865)	-

Net Cash Provided By (Used in) Operating Activities	3,315,678	(648,714)

Cash Flow From Investing Activities:
Capitalized Software Costs	-	(125,704)
Purchase of Property and Equipment	(14,585)	(34,582)
Net Cash (Used in) Investing Activities	(14,585)	(160,286)

The accompanying notes are an integral part of the condensed consolidated financial statements.

	For the Three Months
	Ended March 31
	(Unaudited)
	2020	2019
Numerator:
Net Income (Loss)	$2,619,261	$(934,532)

Trademarks	$512,257	$512,257

Total Intangible Assets, net	$845,663	$939,010

	Three Months Ended March 31, 2020 (Unaudited)	Three Months Ended March 31, 2019 (Unaudited)

Operating lease expense	$39,329	$39,644